The QualityStocks Daily Tuesday, March 10th, 2020

Today's Top 3 Investment Newsletters

PennyStockProphet (AYTU) +489.08%

StockMarketWatch (ENBL) +154.30%

MarketBeat (LPI) +110.85%

The QualityStocks Daily Stock List

American Creek Resources Ltd. (ACKRF)

Gold Telegraph, OTC Markets, hot Stocked, All Stocks Today, Resource World, Barchart, Wallet Investor, Gold Stock Data, Investor Ideas, Seeking Alpha, Equities, GuruFocus, Investing News, Mining News Feed, TradingView, InvestorsHub, moneyhub.net, Dividend Investor, MineStat, Stockhouse, Morningstar, Investing Online, Junior Mining Network, and Market Screener reported beforehand on American Creek Resources Ltd. (ACKRF), and we highlight the Company as well, here at the QualityStocks Daily Newsletter.

American Creek Resources Ltd. is a mineral exploration company with a strong portfolio of gold and silver properties in the Province of British Columbia. It has high quality assets in significant mineral belts of British Columbia (B.C.), close to infrastructure. These include properties in B.C.'s prolific Golden Triangle, one of the richest areas of mineralization in the world. Established in 2004, American Creek Resources is based in Cardston, Alberta.

Three of the Company’s properties are in the prolific "Golden Triangle"; the Treaty Creek and Electrum joint venture (JV) projects with Tudor Gold/Walter Storm and the 100 percent owned past producing Dunwell Mine. An exploration program is continuing on its Dunwell Mine property situated near Stewart. Furthermore, American Creek holds the Gold Hill, Austruck-Bonanza, Ample Goldmax, Silver Side, and Glitter King properties positioned in other prospective areas of the Province.

American Creek Resources earlier announced that its partner, Tudor Gold, concluded the interpretation of a copper-silver mineralized zone, the 'CS 600 Horizon', within the Goldstorm Zone. Composite grades for drill holes GS19-42, 47, 48, 49, 52 and CB18-39 were re-calculated using the copper and silver grades obtained from the 2019 drill-hole program.

The holes are situated in the northeastern-most area of the project. The copper and silver mineralization contributed considerably to increasing the gold equivalent content of all drill holes that cut the new copper-rich 'CS 600 Horizon'.

Last week, American Creek Resources announced the results of gold-equivalent (AuEq) calculations for all drilling completed at JV partner Tudor Gold's flagship project Treaty Creek. The calculations include credit for earlier analyzed values for Cu and Ag. Geological analysis and reinterpretation of all the drill holes to date exposed a new copper horizon (CS 600 horizon) and also significant silver and copper mineralization throughout the Goldstorm system.

The strongest AuEq increase was seen in the newly discovered NE Extension within the 300 Horizon. The gold-only result of 1.27 gpt Au over a 252 meter (m) interval rose to 1.51 gpt AuEq (with 13.8 gpt Ag and 504 ppm Cu). This represents an increase of 18.9 percent. All drill holes at the Goldstorm Zone had substantial increases to the composite results when the AuEq values for the copper and silver mineralization were included.

American Creek Resources Ltd. (ACKRF), closed Tuesday's trading session at $0.046129, off by 12.9642%, on 24,549 volume with 5 trades. The average volume for the last 3 months is 55,260 and the stock's 52-week low/high is $0.016/$0.086000002.

chart

AVRA Medical Robotics, Inc. (AVMR)

Wall Street Reporter, Financial Buzz, EODData, TipRanks, VentureLine, last10k, GuruFocus, Market Screener, BioSpace, Global Banking and Finance, Seeking Alpha, Wallet Investor, Stockhouse, OTC.Watch, GlobeNewswire, MarketWatch, Nasdaq, Dividend Investor, Market Wire News, Dividend.com, Stockopedia, TradingView, Simply Wall St, and TMGPulse reported beforehand on AVRA Medical Robotics, Inc. (AVMR), and today we are reporting the Company, here at the QualityStocks Daily Newsletter.

AVRA Medical Robotics, Inc. is building a fully autonomous medical robotic system through the use of new technologies combining artificial intelligence (AI), machine learning and proprietary software. The OTCQB-listed Company is modernizing the practice of surgery by developing a fully autonomous medical robotic system that “robotizes” a wide spectrum of medical procedures now being performed by human hands utilizing surgical and non-surgical devices and instruments. AVRA Medical Robotics has its corporate office in Orlando, Florida.

AVRA’s medical team were among the earliest adopters to perform robotically assisted, minimally-invasive surgery. The Company’s Surgeons are partnering with engineers and scientists to design and develop a novel, computer-integrated, semi/autonomous robotic platform that is truly disruptive. AVRA is designing systems that will enable surgeons to simulate procedures for preoperative review before performing surgery.

Regarding Imaging, AVRA Medical Robotics’ imaging technology will be capable of high-resolution, multi-dimensional imaging with incorporated scanning and registration. The Company’s technology will be flexible and applicable across a diverse range of medical disciplines.

Concerning Instrument Guidance, the proprietary intelligent AVRA Instrument Guidance System (AIGS) will bring precise navigation and accurate targeting to robotic surgery. This will result in a Surgeon interfaced autonomous platform. Furthermore, AVRA is using its technology to develop ways of considerably improving biopsy result waiting times from weeks or days to minutes.

Last month, AVRA Medical Robotics announced that it paid off almost all of its external corporate debt, including accrued interest. With the exception of loans from the Chief Executive Officer (CEO) and a loan note for $25,000 due December 31, 2020, AVRA has now cleared all its outstanding external debt, with one note of $25,000 being converted into shares at $1.50 per share and the remainder being repaid in full with accrued interest.

Mr. Cohen, AVRA CEO, said, “The repayment of all this Company debt provides further stability to the company’s finances, allowing us to focus on our medical software procedure program and the development of our Autonomous Robotics Surgical System. The potential of our robotic systems is to perform operations with greater precision than human hands are capable of.”

AVRA Medical Robotics, Inc. (AVMR), closed Tuesday's trading session at $0.355, off by 8.9744%, on 3,100 volume with 3 trades. The average volume for the last 3 months is 1,965 and the stock's 52-week low/high is $0.209999993/$2.96000003.

chart

General Cannabis Corp. (CANN)

Zacks, MVP Stock Picks, Savvy Trader Resource, StreetWise Reports, Pot Stock Watch, Infront Analytics, Insider Financial, Green Rush Review, Pot Stock News, Daily Marijuana Observer, Micro Small Cap, Insider Monkey, Micro Cap Daily, OTC Markets, Simply Wall St, Stockhouse, YCharts, CannabisMarketCap, and The Street reported beforehand on General Cannabis Corp. (CANN), and today we report on the Company, here at the QualityStocks Daily Newsletter.

OTCQX-listed, General Cannabis Corp. is the comprehensive national resource to the regulated cannabis industry. It is a trusted partner to the cultivation, production and retail sides of the cannabis business. The Company previously went by the name Advanced Cannabis Solutions, Inc. It changed its name to General Cannabis Corp in June of 2015. General Cannabis has strong operating divisions including real estate, consulting, security, financing and the distribution of vital infrastructure products to grow facilities and dispensaries. General Cannabis is headquartered in Denver, Colorado.

The Company’s family of brands include Next Big Crop (NBC); Iron Protection Group (IPG); and Chiefton. Next Big Crop (NBC) offers first-class management and consulting services. NBC deploys proven solutions for every phase of medical and adult-use cannabis business operations. This is from licensure, design and construction, to the cultivation, manufacture and sale of medical-grade cannabis product.

Iron Protection Group (IPG) is one of the fastest-growing security companies in the nation. IPG’s operators are U.S. Veterans. They are vigilant about education pertaining to regulations in order to ensure that compliance infuses every aspect of its clients’ businesses.

Chiefton works to provide eco-friendly apparel, accessories, as well as printing techniques. Its apparel and accessories use textiles such as hemp, organic cotton, and recycled polyester that deliver performance, comfort, and accountability. In addition, Chiefton uses Denver’s only certifiably green screen-printing shop. General Cannabis’ brands also include GC Capital (Capital Investments Real Estate); Next Big Crop (Operations Consultant and Products); and STOA Wellness (Consumer Goods).

This past January, General Cannabis announced that it signed a purchase agreement to acquire SevenFive Farm, a cultivation facility in Boulder, Colorado. The pending acquisition will now be submitted to the Colorado state regulators (the MED) for approval. The acquisition will close when this approval process is complete.

SevenFive Farm is a 17,000 square feet light deprivation greenhouse cultivation facility that has operated in Boulder county for more than 4 years. General Cannabis expects to improve production in the facility to roughly 300 lbs of flower monthly. The cannabis cultivated at SevenFive will initially sell on the wholesale market and, as the Company adds retail operations, used to partially supply the its dispensaries.

General Cannabis Corp. (CANN), closed Tuesday's trading session at $0.475, up 8.0282%, on 149,677 volume with 175 trades. The average volume for the last 3 months is 164,363 and the stock's 52-week low/high is $0.409999996/$2.0999999.

chart

Genesis Metals Corp. (GGISF)

Stock News Now, OTC Markets, 24hgold, Morningstar, Streetwise Reports, InvestorsHub, Business Insider, Investing.com, 4-Traders, Morningstar, Equities, Barchart, Nasdaq, Simply Wall St, Junior Mining Network, Energy and Gold, MarketWatch, Dividend Investor, Stockhouse, YCharts, and Newsfile Corp reported earlier on Genesis Metals Corp. (GGISF), and we also highlight the Company, here at the Quality Socks Daily Newsletter.

Genesis Metals Corp. engages in the acquisition and exploration of mineral property interests in Canada. It is focused on the Chevrier Gold Project in the southwest of Chibougamau, Quebec. In addition, the Company has also earned a 100 percent interest in the 200 square km October Gold property in the Province of Ontario. Genesis Metals has its corporate office in Vancouver, British Columbia. The Company lists on the OTC Markets Group’s OTCQB. Genesis Metals is a Member of the Discovery Group of Companies.

As of February 2019, Genesis Metals announced an updated resource estimate for the 100 percent owned Chevrier Gold Project. The new 43-101 resource estimate includes 423,000 ounces Indicated at 1.22 g/t Au and 303,000 ounces Inferred at 1.27 g/t Au at Chevrier. The high grade gold component of the known resource was not the focus of historical exploration.

The Chevrier Gold Project is a large property (+290km²) with potential for new high-grade discoveries. The deposits are open for expansion with high-grade areas not yet systematically targeted. The Project covers 15 km of the gold-endowed Fancamp Deformation Zone. There is the potential to expand the tonnage and the grade of existing resources.

Furthermore, Genesis Metals has earned a 100 percent interest in the 200 square km October Gold Property in Ontario. The property bestrides the underexplored Southern Swayze Greenstone belt on trend to Goldcorp’s Borden Lake deposit and Iamgold’s Cote Lake deposit. Both of the Company’s projects are easily accessible and near infrastructure.

The October Gold Property encompasses 203 square kilometers. The Company’s past surface exploration program identified two strong gold anomalies at October Gold. One has a footprint of 1.5km by 3km; the other has a footprint of 2.0km by 2.0km. Both anomalies have a high degree of confidence.

Last month, Genesis Metals provided a summary of results for the 2019 program and an overview of current 2020 exploration plans for its Chevrier Gold Project in the eastern Abitibi Greenstone Belt of Central Quebec. Selected significant achievements in 2019 include a new mineral resource estimate for the Main and East zones with Indicated Resources of 395,000 oz gold averaging 1.45 g/t and Inferred Resources of 297,000 oz gold averaging 1.33 g/t. Achievements also include a property-wide glacial till survey that resulted in the identification of compelling new gold targets outside of known mineralized zones.

Genesis Metals is fully funded for its currently planned 2020 exploration program. The 2020 exploration program is concentrating on targeting high-grade zones with drilling, evaluation and testing of new gold targets.

Genesis Metals Corp. (GGISF), closed Tuesday's trading session at $0.1905, off by 16.41%, on 2,000 volume with 2 trades. The average volume for the last 3 months is 5,791 and the stock's 52-week low/high is $0.14/$0.3438.

chart

Puration, Inc. (PURA)

Street Insider, Small Cap Exclusive, Beat Penny Stocks, OTC PR Wire, GuruFocus, Stock of the Week, Stockopedia, CannabisMarketCap, OTC Markets, Global Banking and Finance, TradingView, Nasdaq, GlobeNewswire, StockInvest.us, InvestorsHub, Insider Financial, Proactive Investors, Market Screener, PR Newswire, Stockhouse, Wallet Investor, NIC Investors, and TMXmoney reported earlier on Puration, Inc. (PURA), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

Puration, Inc. is the producer of EVERx CBD Infused Sports Drink, the top CBD (cannabidiol) beverage in the sports nutrition marketplace. The Company launched the EVERx CBD Infused Sports Waters in the Spring of 2017. Its sales grew 600 percent in the first year after the launch of EVERx. Puration is based in Farmers Branch, Texas. The Company lists on the OTC Markets.

The Company is reorganizing to center its efforts on the cannabis beverage industry. It is implementing an acquisition campaign targeting other cannabis beverage operations as part of an overall strategy to hasten an expansion of its portfolio of cannabis beverage brands.

Puration announced in December 2019 entering into a contract to begin bottling EVERx CBD Sports Water in Europe. Puration also announced acquiring a company to facilitate bottling in Europe as part of an overall initiative to expand bottling capacity worldwide. The Company also signed a distribution agreement in Europe estimated to add $4 million in sales this year.

Puration earlier announced it anticipates doubling its 2020 $8 million revenue target with the introduction of its new white label cannabis infused beverage bottling business. It announced entering into the white label cannabis infused beverage production sector leveraging its cannabis infused beverage formulation and production experience and its expanding bottling capacity to capture a much larger portion of the overall global cannabis beverage sector.

On March 6, 2020, Puration announced that Puration and Kali-Extracts, Inc. plan to close their earlier announced CBD Confections deal next Friday, March 13th. PURA is acquiring KALY's CBD Confections operation. KALY has developed the Hemp4mula CBD Confections line that today sells CBD infused gummies and gum. KALY is selling the operation to streamline its emphasis on its ongoing cannabis biopharmaceutical business. Puration recently announced the acquisition of a CBD Infused Pet Products operation. The seller presently provides concierge pet services via an online portal. The CBD Infused Pet Product Line will bear the name of the portal. Puration will have access to the portal and the existing customer base in conjunction with the purchase agreement.

Puration, Inc. (PURA), closed Tuesday's trading session at $0.02405, up 9.3182%, on 1,964,692 volume with 172 trades. The average volume for the last 3 months is 3,055,967 and the stock's 52-week low/high is $0.0218/$0.102499999.

chart

SStartrade Tech, Inc. (SSTT)

Emerging Growth, Penny Stock Hub, InvestorsHub, Nasdaq, Morningstar, TipRanks, Stockopedia, Market Screener, Wallet Investor, Investors Hangout, TradingView, OTC Markets, OTC.Watch, Barchart, YCharts, Seeking Alpha, Simply Wall St, Dividend.com, Market Wire News, GuruFocus, Dividend Investor, and Investing.com reported earlier on SStartrade Tech, Inc. (SSTT), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

SStartrade Tech, Inc. concentrates on using its strong capital position, extensive industry contacts and expertise to identify, evaluate, and invest in quality gold mining assets. It holds a 74 percent interest in the voting shares of Swiss corporation, SStarTrade SA, which aims to develop million ounce gold deposits in the Russian Federation. The Company’s strategic objective is to become, by 2021, a cost-effective gold-mining enterprise of medium scale and produce a minimum 4,250 kg of gold annually. SStartrade Tech has its head office in New York, New York.

The principal activity of SStartrade Tech is the organization of financing and the implementation of an investment project in the field of gold mining at the Kadara gold deposit in the Trans-Baikal Territory, in the Russian Federation. This project includes an investment attraction to create a gold mining company with the initial resource base of 177 tons of gold. The project foresees financing of prospecting works for confirmation of the gold reserves and construction of a gold-processing complex.

The product of the Kadara deposit is Ingot gold. The field is a license area with a total area of 185.8 sq.km. It has cumulative forecast resources of categories P1 and P2 - 177,53 tons of gold. The plan sales volume is 8.5 tons of gold annually. The structure of the gold recovery complex will include the following main subdivisions: ore extraction and ore dressing department, hydrometallurgical department, pre-production area and the tailing unit.

The Kadara gold ore field is in the Mogochinsky district of the Trans-Baikal Territory, between the Shilka River and the Amazar River. The Yerofey Pavlovich railway stations are 50 km away and the Amazar railway station of the Trans-Baikal Railway is 65 km away. The field area is linked with the Amazar and Yerofey Pavlovich settlements by dirt roads. The benefits of the project are based on its main feature - the establishment of a gold mining company engaged in the sphere of gold mining with a long-term perspective of extracting at least 8.5 tons of gold a year for 20 years.

The project promoter is the abovementioned SStarTrade SA, a Swiss consulting company. Since 2005, SStarTrade SA has been engaged in financial and legal consulting. It also acts as managing company for several global projects.

SStartrade Tech, Inc. (SSTT), closed Tuesday's trading session at $0.10, even for the day, on 3,956 volume. The average volume for the last 3 months is 1,656 and the stock's 52-week low/high is $0.035/$0.239999994.

chart

urban-gro, Inc. (UGRO)

Street Insider, TipRanks, Stockopedia, last10k, Market Screener, Penny Stock Hub, Proactive Investors, Wallet Investor, Loud News Net, Cannabis Business Executive (CBE), Simply Wall St, Stockhouse, GlobeNewswire, Nasdaq, Dividend.com, Dividend Investor, Barchart, PR Newswire, Morningstar, InvestorsHub and MarketWatch reported previously on urban-gro, Inc. (UGRO), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

urban-gro, Inc. is an engineering design services company listed on the OTC Markets’ OTCQX. It integrates complex equipment systems into high-performance indoor cannabis cultivation facilities around the world. The Company bring decades worth of combined commercial cultivation experience to craft fully-integrated systems and technology solutions. urban-gro has its corporate headquarters in Lafayette, Colorado.

With its With Soleil Technologies line of sense and control technology, cultivators are able to monitor their canopy and grow environment conditions from anywhere, 24/7. With its foundational Cultivation Space Planning design services, urban-gro creates cultivation facilities that surpass its customers’ goals for efficient interaction between the people, plants, and processes.

Urban-gro had customized product solutions to meet the needs of commercial cultivators. It provides professionally designed bench plans that maximize cultivation space and provides custom fertigation design unique to a customer’s facility and its needs and challenges. The Company also provides LED, HPS, CMH and Hybrid Lighting Solutions. It also provides Pest Control and Water Treatment.

Integrated Pest Management (IPM) promotes healthy, relatively pest-free crops. Moreover, urban-gro partners with HydroLogic to provide efficient, high-end commercial water filtration systems.

Urban-gro designs custom biological wastewater treatment systems to decrease the levels of salts and BODs before emission to the sewer. The Company’s services include Cultivation Systems Design, MEP Building Engineering, Commissioning and Start-Up, the above-mentioned Integrated Pest Management, Odor Mitigation, and Crop Monitor Technology.

Pertaining to Integrated Design Services, urban-gro is an agricultural solutions enterprise focusing on systems integration and ag-tech for cannabis and high-value food crop markets. The Company is a recognized national leader in the design, equipment procurement, project management, installation oversight, and commissioning of cultivation facility systems. To date, urban-gro has delivered greater than 5,000,000 square feet of facilities across the United States and Canada.

Concerning Commissioning and Facility Start-Up, the Company’s comprehensive commissioning report and checklist provides a client with the confidence that their systems are operating efficiently. In addition, urban-gro’s process includes documentation of their systems and training of staff so they can effectively manage systems.

urban-gro, Inc. (UGRO), closed Tuesday's trading session at $1.00, even for the day, on 1,150 volume. The average volume for the last 3 months is 1,177 and the stock's 52-week low/high is $1.00/$2.5999999.

chart

eMARINE Global, Inc. (EMRN)

TipRanks, Real Investment Advice, StockPulse, TeleTrader, Wallmine, Market Wire News, TradingView, Street Insider, Wallet Investor, Stockhouse, Market Screener, InvestorsHub, Morningstar, Stockopedia, Nasdaq, GlobeNewswire, Global Banking and Finance, Stockwatch, Simply Wall St, and Financial Buzz reported beforehand on eMARINE Global, Inc. (EMRN), and today we report the Company, here at the QualityStocks Daily Newsletter.

eMARINE Global, Inc. is a top provider of information and communications technology (ICT) for the maritime industry. It provides solutions for the collection, integration and display of maritime information abroad and ashore through electronic means to enhance berth to berth navigation and related services. The Company formerly went by the name Pollex, Inc. It changed its name to eMarine Global, Inc. in August of 2017. Incorporated in 2001, eMARINE Global has offices in Ulsan and Seoul, South Korea.

eMARINE Global’s solutions provide the most efficient means to secure the safety of life at sea and to protect the marine environment. All products and services are offered through subscription, installation, updates and/or maintenance contracts.

eMARINE Global is working with a growing base of marquee customers to reach maritime ICT convergence by way of fully integrated products and services. The Company offers state-of-the-art e-navigation, marine Internet of Things (IoT), and marine big data solutions, primarily in Korea with near-term expansion into U.S. and Chinese markets.

eMARINE Global offers electronic chart display and information systems (ECDIS), a computer-based navigation system; and electronic navigation charts (ENC), which integrates position information from the global positioning system (GPS) and other navigational sensors, including radar, fathometer, and automatic identification systems. eMARINE Global also provides smart ship solutions, including intra-ship integrated gateway (ISIG), an intra-ship network; collision avoidance and optimal voyage systems; and remote maintenance and engine monitoring systems.

The Company engages in the distribution of overseas solutions, such as CARIS, a maritime GIS software; digital charts; and Hatteland, a maritime-specialized hardware. Moreover, it provides Aids to Navigation (AtoN) management systems consisting of maritime weather signals total management system, and e-A2N device.

Recently, eMARINE Global announced it was chosen as the preferred bidder for a large-scale vessel traffic system (VTS) project for the Korean Coast Guard. The Company will work with foremost domestic system integrators, including Daily Blockchain and STX Engine, to complete the VTS project. In addition, the project team will include worldwide surveillance solution providers, including SAAB, an eMARINE partner company, and Terma A/S. The Korean Coast Guard VTS project is budgeted at $14 million over two years.

With the negotiated terms of the contract, the project consortium will construct two VTS operating centers, one in Mokpo and one in Gunsan, both located on the southwest coast of Korea. The project will include three radar systems in Mokpo and two radar systems in Gunsan.

eMARINE Global, Inc. (EMRN), closed Tuesday's trading session at $0.20, up 185.7143%, on 6,000 volume with 2 trades. The average volume for the last 3 months is 909 and the stock's 52-week low/high is $0.0131/$4.00.

chart

FingerMotion, Inc. (FNGR)

Stock Target Advisor, OTC Markets, Capital Cube, Stockwatch, Investors Hangout, Stockhouse, Real Investment Advice, Trading View, InvestorsHub, Street Insider, Simply Wall St, and Wallet Investor reported beforehand on FingerMotion, Inc. (FNGR), and today we report on the Company, here at the QualityStocks Daily Newsletter.

FingerMotion, Inc. is a U.S. FinTech (Financial Technology) company with mobile payment and recharge platform operations in the People’s Republic of China (PRC). It is one of five companies in China with access to wholesale rechargeable minutes by way of top-up credits on the mobile phone. The Company’s vision is to quickly grow its user base via organic means and have this growth develop into an ecosystem of users with high engagement rates using its unique applications.

JiuGe Information Technology is FingerMotion’s wholly-owned Chinese subsidiary. FingerMotion has its head office in China. The Company’s shares trade on the OTC Markets Group’s OTCQB.

FingerMotion is investing in research and development (R&D). Its chief area of emphasis is the development of “must have” applications for consumers and businesses. Its longer term focus is to develop a marketing platform capable of leveraging all the meta data collected by the leading telcos into a predictive model, which is able to isolate and extract consumer behavior and habits for future monetization.

FingerMotion is developing value added technologies to market to its users. The Company ultimately hopes to serve more than 1 billion users in the China market and eventually expand the model to other regional markets.

In late October 2019, FingerMotion announced its financial results for the quarter ended August 31, 2019. Chief Executive Officer, Mr. Martin Shen, said, “I am very pleased with the improvement in our JiuGe subsidiary, as we posted our first ever gross profit for the quarter. We believe this achievement has elevated us to an elite class of Chinese e-commerce businesses that have reached profitability.”

The latest financial results reflect an improved balance sheet and quarter-over-quarter growth. FingerMotion maintained momentum in their Revenues mainly driven by their strategic partnerships regarding top-up growth. Its Gross Transaction Volume (GTV) for Q2 was $181 million. This represents a 15 percent quarter over quarter increase in comparison to the $157 million realized in Q1. This translates to an annual run rate of $722 million.

The Company stated that the SMS business is also gaining noticeable traction. Moreover, the JiuGe subsidiary was awarded contracts to market China Mobile’s products and services online, in ShanXi and SiChuan provinces, which have a combined population of greater than 115 million people.

FingerMotion, Inc. (FNGR), closed Tuesday's trading session at $0.7999, up 59.98%, on 16,400 volume with 16 trades. The average volume for the last 3 months is 3,550 and the stock's 52-week low/high is $0.400000005/$9.4499998.

chart

Medibio Limited (MDBIF)

Awesome Penny Stocks, Wallet Investor, The Street, TradingView, Morningstar, Penny Stock Hub, Stockwatch, OTC Markets, Investing Online, Otc.Watch, Investors Hangout, Stockhouse, 4-Traders, and Global Banking and Finance reported earlier on Medibio Limited (MDBIF), and today we choose to report on the Company, here at the QualityStocks Daily Newsletter.

Medibio Limited is a digital health company with offices in Melbourne (Vic), and Minneapolis, Minnesota. It has developed an objective testing system to assist in the screening, diagnosis, and treatment effectiveness of depression, chronic stress, and other mental health disorders. The test uses patented (and patent pending) circadian heart rate variability and cloud based proprietary algorithms to deliver a quantifiable measure to assist in clinical diagnosis. Medibio lists on the OTC Markets’ OTCQB.

Medibio is on course to commercialize its platform technology called the Digital Mental Health Platform. The basis of this is on patented biomarkers from the autonomic nervous system. The Company’s technology will provide a Diagnosis Aid to help General Practioners (GPs) and mental health clinicians. Medibio’s technology provides the first objective measure of stress. It provides a series of user and corporate dashboards for assessment and wellness partner interventions.

Regarding biomarker based objective diagnosis, a panel of circadian, sleep, and automatic system biomarkers enables automated, repeatable, and objective characterization of the impact of mental illness on the physiologic state. Medibio’s Digital Mental Health Platform is a device agnostic platform. It can ingest data from many devices. It is highly scalable, low cost, as well as easy to integrate.

Medibio announced in October 2018 the release of ilumen™. This is its product and platform for corporate customers. ilumen™ is a corporate wellness product providing employers the ability to offer biometric analysis and objective, data-driven feedback along with a mental wellness assessment to their employees.

This past November, Medibio announced that it signed an exclusive agreement with AIAA to undertake a pilot program for the latest release of its corporate health program, ilumen™. AIAA is one of Australia’s leading life insurers. AIAA is part of the AIA Group, which is the largest independent publicly listed pan-Asian life insurance group. It has a presence in 18 markets around the Asia-Pacific region. AIAA will have access to ilumen™ over a six-month period for its Australia and New Zealand employees.

Medibio Limited (MDBIF), closed Tuesday's trading session at $0.0079, up 58.00%, on 55,000 volume with 4 trades. The average volume for the last 3 months is 10,462 and the stock's 52-week low/high is $0.0013/$0.029999999.

chart

Sutter Gold Mining, Inc. (SGMNF)

Penny Stock Hub, Stockhouse, Streetwise Reports, InvestorsHub, 4-Traders, MarketWatch, Investors Hangout, Cardinal Weekly, TradingView and The Northern Miner reported on Sutter Gold Mining, Inc. (SGMNF), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

Sutter Gold Mining, Inc. engages in the exploration of mineral properties. The Company primarily explores for gold deposits. Sutter currently controls a considerable land position of the Mother Lode in California. The Company has advanced work and exploration programs completed on surrounding land holdings. Sutter Gold Mining has its management office in Lakewood, Colorado. It has its mine office in Sutter Creek, California. The Company lists on the OTC Markets Group’s OTCQB.

Sutter Gold Mining has two projects. One is the Lincoln Project situated in Amador County, on the California Mother Lode Gold Belt. The other is the Santa Teresa Project situated in the Northern Baja area of Mexico.

Regarding Mexico and the Santa Teresa Concession, the Company entered into an exclusive option agreement with The Alamo Group in October of 2006 to acquire a 100 percent interest in the Santa Teresa Mineral Concession. Santa Teresa is in the historic El Alamo gold mining district, southeast of Ensenada. The property is positioned contiguous to and on strike with the past-producing Princessa Mine.

Sutter Gold released in 2009 the assay results from the initial 32-hole Phase 1 program. The results included intercepts as high as 21.10 grams per ton or 0.62 ounces of gold per ton across 1.35 meters and 16.68 g/t of gold across 3.1 meters. These results continued to reveal the potential of this underexplored district. In addition, the results confirmed manifold high-grade veins up to 260 meters along strike from the historic Princessa Gold Mine and that all known structures remain open in all directions.

Sutter Gold Mining also holds the rights to the geologically similar, high-grade El Alamo district of northern Baja in Mexico. This is where historic mining to the water table produced mined grades of 30 to 60 g/t gold.

Regarding the Sutter Gold Project, California, the Lincoln and Comet properties are located on a 551-acre block of mining claims and surface rights 45 miles east southeast of Sacramento, California, in the central part of the 121-mile-long Mother Lode gold belt.

Sutter Gold Mining, Inc. (SGMNF), closed Tuesday's trading session at $0.0009, up 50.00%, on 90,200 volume with 2 trades. The average volume for the last 3 months is 31,280 and the stock's 52-week low/high is $0.000000999/$0.013299999.

chart

Acura Pharmaceuticals, Inc. (ACUR)

CRWEWallStreet, PennyToBuck, StreetInsider, Marketbeat,  SmarTrend Newsletters, Wall Street Resources, PennyOmega,  PennyStocks24,  Penny Stock Rumble, The Street, BestOtc, BUYINS.NET,  CRWEFinance, StockHotTips, and DrStockPick  reported on Acura Pharmaceuticals, Inc. (ACUR), and today we report on the Company, here at the QualityStocks Daily Newsletter.

Acura Pharmaceuticals, Inc. is a specialty pharmaceutical company innovating abuse deterrent drugs. It engages in the research, development, and commercialization of product candidates intended to address medication abuse and misuse,  utilizing its proprietary LIMITx™, AVERSION®, and IMPEDE® Technologies. OTCQB-listed, Acura Pharmaceuticals is based in Palatine, Illinois.

The patented LIMITx technology works by neutralizing stomach acid with buffering ingredients as increasing numbers of tablets are swallowed. It relies on stomach acid to play a role in the release and subsequent systemic absorption of the active ingredient from micro-particles contained in the tablets.

The intention of the  LIMITX™ Technology is to address an oral Excessive Tablet Abuse (ETA) or accidental consumption of multiple tablets and provide a margin of safety during accidental over-ingestion of tablets. Additionally, LIMITX™ is expected to exhibit barriers to abuse by snorting and injection. LTX-04 is Acura’s lead development candidate employing its novel LIMITx™ technology.

AVERSION® Technology is a patented composition of commonly used active and inactive pharmaceutical ingredients providing abuse deterrent features and benefits for orally administered pharmaceutical drug products. The intention of AVERSION® Technology opioid analgesic product candidates is to provide effective relief from pain. This is while discouraging common methods of pharmaceutical product misuse and abuse.

OXAYDO® (oxycodone HCl immediate-release tablets), which incorporate the AVERSION Technology, is Food and Drug Administration  (FDA) approved and marketed in the  United States by Acura’s partner Egalet Corp. 

The IMPEDE® Technology platform is an advanced polymer matrix. It is used in NEXAFED®,  Acura Pharmaceuticals’ pseudoephedrine (PSE) tablet product, to limit or disrupt the extraction of PSE from tablets for conversion into the illicit drug methamphetamine. 

NEXAFED® and NEXAFED® Sinus are pseudoephedrine containing products that use the IMPEDE Technology. They are marketed in the United States by Acura Pharmaceuticals’ partner MainPointe Pharmaceuticals.

Recently, Acura Pharmaceuticals announced financial results for the three and six months ended June 30, 2018. Acura reported a Net Loss of $2.8 million or $0.13 per diluted share for the six months ended June 30, 2018, versus a Net Loss of $1.7 million or $0.15 per diluted share for the same period in 2017. For the Q2 2018, it reported a Net Loss of $1.3 million or $0.06 per diluted share versus a Net Loss of $2.2 million or $0.18 per diluted share for the same period in 2017.

Acura Pharmaceuticals, Inc. (ACUR), closed Tuesday's trading session at $0.40, up 59.936%, on 6,452 volume with 10 trades. The average volume for the last 3 months is 9,696 and the stock's 52-week low/high is $0.119999997/$0.629999995.

chart

Advanced BioMedical Technologies, Inc. (ABMT)

Zacks, Stockrow, and 4-Traders reported on Advanced BioMedical Technologies, Inc. (ABMT), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

Advanced BioMedical Technologies, Inc. manufactures and distributes advanced impedance controlled micro-current instruments.  The Company has treated more than 15,000 patients during the past 28 years. It is a leader in education, research, training, and instrument sales and works with doctors and clinicians throughout the U.S. This includes those in Minnesota, the majority of which have an affiliation with the University of Minnesota. Advanced BioMedical Technologies is based in Eagan,  Minnesota.

The Company is the oldest distributor of the Electro-Acuscope and Electro-Myopulse. Advanced BioMedical has a 6,000-square foot office complex, with 3,000 square feet dedicated as a patient care treatment center.

The Electro-Acuscope and Electro-Myopulse instruments feature the most sophisticated computerized, feedback-controlled, energy delivery, micro-current technology available today. Acuscope products include the Electro-Acuscope 85P (Portable); the Electro-Acuscope 80L; and the Neuroscope 230B. Myopulse products include the Electro-Myopulse 75L (Base Model) and the Electro-Myopulse 75F (used in Fermi Lab Study).

The Electro-Myopulse measures the Bio-Impedance of the muscle tissue between the two electrodes. Similarly, this is how the current amplitude and voltage output is adjusted and controlled. The Myopulse uses a sine wave. This sine wave imitates the wave produced when a muscle first contracts.

The Electro-Acuscope monitors nerve conduction between two electrodes. This is how the current amplitude and voltage output is adjusted and controlled. The Acuscope uses a complex waveform. This waveform imitates a nerve impulse.

The Neuroscope 230B (Home Care Unit) is for the personal treatment of sleep, anxiety,  and pain issues. The product is a personal treatment device for the person on the go. Moreover, it is as an adjunct to Acuscope and Myopulse (impedance controlled microcurrent) therapy where extended rehabilitation therapy  require  more treatments at home.  

The design of the Electro-Acuscope 85P (Portable)  instrument is for the traveling clinician or patient (with prescription). This instrument is built into a haliburtor case for safe and easy portability.

Furthermore, Advanced BioMedical Technologies has its La Fleur products. These include the Electro-Myopulse 75LN Premium Instrument (Myopulse, Facial and Esthetics), which was developed exclusively by the Company. In addition, the Company carries a line of Accessories.

Recently, Advanced Biomedical Technologies announced that the State Intellectual Property Office of The People’s Republic of China (SIPO) issued the Company a new patent titled “Bone Fracture Plate Made of High Polymer Materials”. Its subsidiary Shenzhen Changhua Biomedical Engineering Company Limited is entitled for the new patent (ZL 2014 1 0647464.1), which strengthens the Company's position in manufacturing process and related controls using its innovative polyamide materials (PA).

Advanced BioMedical Technologies, Inc. (ABMT), closed Tuesday's trading session at $0.19, up 352.381%, on 100 volume with 1 trade. The average volume for the last 3 months is 508 and the stock's 52-week low/high is $0.012/$0.321999996.

chart

RepliCel Life Sciences, Inc. (REPCF)

OTCPicks, Greenbackers, Investor Spec Sheet, StockGuru, TheStockAdvisor, 24-7 Stock Alert, Beacon Equity Research, Crazy Carl, Global Equity Report, The Green Baron, Club Penny Stocks Network, Streetwise Reports, InvestorSoup, Penny Stock Explosion, SmallCapReview, Stock Preacher, Penny Stocks Finder, ShazamStocks, and StockHideout reported earlier on RepliCel Life Sciences, Inc. (REPCF), and today we report on the Company, here at the QualityStocks Daily Newsletter.

RepliCel Life Sciences, Inc. is a regenerative medicine company listed on the OTC Markets’ OTCQB. The Company concentrates on the development of cell therapies for aesthetic and orthopedic conditions. These include aging/sun-damaged skin, pattern baldness, and chronic tendon degeneration. All of its product candidates are based upon RepliCel’s unique technology using cell populations isolated from a patient's healthy hair follicles. RepliCel Life Sciences has its headquarters in Vancouver, British Columbia.

The Company’s product pipeline consists of RCT-01 for tendon repair, RCS-01 for skin rejuvenation, as well as RCH-01 for hair restoration. Currently, RCH-01 is being co-developed with, and under exclusive license by, Shiseido for certain Asian countries. In addition, RepliCel has developed a proprietary injection device RCI-02, optimized for the administration of its products and licensable for use with other dermatology applications.

RepliCel Life Sciences is investing in research that the Company states has the potential to lead to a number of future products. These include other chronic tendinopathies (patellar tendinosis, tennis elbow, golfer’s elbow, rotator cuff); other dermatologic indications (acne scaring, etc.); gingivitis, and allogeneic versions of the Company’s proven autologous cell therapies.

In September 2017, RepliCel Life Sciences announced the timely arrival of its functioning RCI-02 prototypes. These became ready to be showcased to potential end users and licensing partners.

With these prototypes in-hand, the Company is engaging with important opinion leaders and clinical dermatologists to ask for feedback vitally important to aligning successful early adoption of the device, design clinical studies demonstrating its advantages in select applications, and position RepliCel for an anticipated successful launch of an approved next-generation dermal injector in the European market this year.

Recently, RepliCel Life Sciences announced that it signed a Binding Term Sheet with YOFOTO (China) Health Industry Co. Ltd. (YOFOTO) to establish a strategic partnership in Greater China (Mainland China, Hong Kong, Macau, and Taiwan). The deal involves an up-front investment of USD $6,500,000 and potential pre-commercial, non-dilutive milestones payments of another USD $2,800,000.

Moreover, the Term Sheet commits YOFOTO to another USD $1,000,000 in potential post-commercial non-dilutive milestone payments, several million in dedicated program funding in Greater China over the next five years, and future royalty payments calculated on gross product sales in the Territory.

RepliCel Life Sciences, Inc. (REPCF), closed Tuesday's trading session at $0.23505, up 64.0838%, on 120,375 volume with 23 trades. The average volume for the last 3 months is 18,214 and the stock's 52-week low/high is $0.105099998/$0.354000002.

chart

The QualityStocks Company Corner

Trxade Group Inc. (NASDAQ: MEDS)

The QualityStocks Daily Newsletter would like to spotlight Trxade Group Inc. (NASDAQ: MEDS).

Trxade Group, Inc. (NASDAQ: MEDS), an integrated drug procurement, delivery and healthcare platform, today announced the onset of a new membership service by its subsidiaries Bonum Health and DelivMeds. According to the update, the monthly subscription rate of $19.95 now includes an option of three (3) premium visits per month as well as free prescription delivery service through its subsidiaries. To view the full press release, visit http://nnw.fm/RgR9e.

Trxade Group Inc. (NASDAQ: MEDS) is an integrated pharmaceutical services company that offers a unique combination of a web-based purchasing platform (www.trxade.com) for transactions between independent pharmacists and drug distributors (B2B); a network of pharmacies with E-Hub software; a mail order pharmacy; and warehouse and drug delivery services. This synergistic combination of product offerings and superior data analytics is poised to benefit all stakeholders and consumers within the pharmaceutical industry.

Trxade will leverage and scale its fully integrated model to execute the following growth strategies:

  • Increase share of pharmacist drug purchasing
  • Additional SKUs and expand product breath
  • Partner with Specialty and International Mfg.
  • Expand mail order licenses to all 50 states
  • Scale Delivmeds for consumer delivery nationwide
  • Integration with telemedicine
  • M&A Opportunities within drug value chain

Founded in 2010 and headquartered in Tampa, Florida, Trxade’s overarching corporate strategy is to penetrate the existing retail independent pharmacy marketplace and diversify the company’s pharmaceutical mix with additional specialty and acute care products. Trxade is advancing on this mission by focusing on three key niches in the health care market.

Business-to-Business (B2B)

The $330 billion U.S. pharmaceutical industry is comprised of more than 65,000 pharmacy facilities and 1,500 state-licensed suppliers. Roughly 24,000 of these facilities are independent pharmacies, which collectively spend approximately $93 billion a year on branded and generic drugs.

Trxade targets these independent pharmacies, leveraging a robust, “E-Bay/Kayak-like” technology platform with optimum buyer/seller pricing algorithms, product availability, and predictive data analytics features.

Trxade currently serves and transacts with more than one-third (10,250) of these independent pharmacies and facilitates over $10 million of drug purchases a month!

Consumer

Trxade also targets the “consumer side” of the pharmaceutical industry, aiming to lower prescription drug costs by attacking the inefficient value chain; offering drug price transparency and efficient buying; and, delivering drugs DIRECT to independent pharmacists and consumers.

The company operates a full-service mail order pharmacy for U.S. consumers, as well as a mobile app called “Delivmeds” (http://www.delivmeds.com) which enables SAME DAY home delivery of dispensed prescriptions.

Retail

Trxade’s Managed Services Organization (“TrxadeMSO”) enables its member independent retail pharmacies to get patients, process orders, and deliver or ship prescriptions to patients. TrxadeMSO provides access to encompassing network of pharmacies through the E-Hub software, allowing for timely and comprehensive medication fulfillment.

These offerings ensure the best-suited pharmacy receives the patient’s information, thereby ensuring appropriate medication coverage based on the patient’s location, payor coverage, and medication access/inventory. This will save the clinicians and their staff time as they benefit from efficiency and enhanced workflow management in script processing and fulfillment.

Health Care Market

The U.S. health care market currently hovers near $4 trillion and is expected to grow as the general population ages. This growth will have greater impact on consumers as out-of-pocket expenses also rise. Additionally, drug costs are paced to increase faster than the overall health care and well above inflation.

Drug pricing is variable, and reimbursement is squeezing profits. This provides significant opportunity for the Trxade model of price visibility and profit optimization.

Trxade’s fair online market platform targets the nation’s retail community and independent pharmacies, of which there are approximately 24,000 nationwide. TRxADE has found that independent pharmacies, in order to be cost-effective, often operate with minimal staff and conduct up-to-the minute price checks. The TRxADE S2P platform gives these pharmacists the ability to easily compare the price of drugs offered by various suppliers and select the most favorable deals, saving money by taking advantage of best purchase pricing.

TRxADE’s programs include:

  • TRxADE Exchange, which opens and widens the distribution channel to the retail, community pharmacy. A purchasing pharmacy can view products from manufacturers, buying groups, and wholesalers on a real-time and continuous basis. This approach significantly enhances the competitive spirit of the exchange where the lowest price exists for each product at any given point in time. TRxADE has become a competitive tool for all progressive entities and is recognized for its easy searching of hard-to-find generic pharmaceuticals at substantially reduced prices.  
  • RX Guru™ is an industry-leading price prediction model that integrates product shortage insight into pharmacy acquisition benchmarks (“PAC”) to ascertain trends and pricing variances that result in significant purchasing opportunities. RX Guru affords members the opportunity to continuously benefit from real price purchasing opportunities that are concealed from the rest of the industry. 
  • Product Shortage Database – TRxADE maintains the most comprehensive retail, specialty and acute care pharmaceutical product shortage database in the country. Other industry competitors mainly restrict their efforts to specialty and acute care product shortages and narrowly research oral generic products. TRxADE’s advanced prediction tools help members source those hard-to-find products at affordable costs in a timely and easy-to-search process. 

Management Team 

Trxade’s management team is rich in expertise within the pharmaceutical supply chain and is supported by a base of advisors and contractors who are experts in related fields of the pharmaceutical sector.

Suren Ajjarapu – Chairman of the Board, Chief Executive Officer and Secretary
Suren Ajjarapu has served as Trxade’s chairman of the board, CEO and secretary since 2014, and as the chairman of the board, chief executive officer and secretary of Trxade Nevada since its inception. Ajjarapu also serves as a chairman of the board for Feeder Creek Group Inc., since March 2018. Ajjarapu formerly was a founder, CEO and chairman of Sansur Renewable Energy Inc., a company involved in developing wind power sites in the Midwest, United States; a founder, president and director of Aemetis Inc., a biofuels company (AMTX.OB); a founder, chairman and CEO of International Biofuels, a subsidiary of Aemetis Inc.; and a co-founder, COO, and director at Global Information Technology Inc., an IT outsourcing and systems design company. Ajjarapu holds an M.S. in environmental engineering from South Dakota State University, Brookings, South Dakota, and an MBA from the University of South Florida, specializing in international finance and management. Ajjarapu is also a graduate of the Venture Capital and Private Equity program at Harvard University.

Prashant Patel – Director, President and Chief Operating Officer
Prashant Patel has served as Trxade’s full-time president and COO, and as a director since the company’s acquisition of Trxade Nevada in 2014, and as the COO and president and as a director of Trxade Nevada since its inception. He has been a president and member of the board of Trxade since August 2010. Patel is a registered pharmacist and pharmaceutical consultant with over 10 years of experience in retail pharmacy and pharmaceutical logistics. He is the founder of several pharmacies in the Tampa Bay area, in Florida. Since 2008, Patel has been managing member of the APAA LLC pharmacy. Since 2007, Patel has been a vice president of Holiday Pharmacy Inc. Patel graduated from Nottingham University School of Pharmacy and practiced in the United Kingdom before obtaining his masters in Transport, Trade and Finance from Cass Business School, City University, UK.

Trxade Group Inc. (MEDS), closed Tuesday's trading session at $5.22, up 24.2857%, on 1,738 volume with 24 trades. The average volume for the last 3 months is 15,367 and the stock's 52-week low/high is $2.0999999/$10.5600004.

Recent News

chart

Exro Technologies Inc. (CSE: XRO) (OTCQB: EXROF)

The QualityStocks Daily Newsletter would like to spotlight Exro Technologies Inc. (OTCQB: EXROF).

Exro Technologies Inc. (CSE:XRO; OTCQB:EXROF) (the "Company" or "Exro") announces that it has granted incentive stock options to certain directors, officers, employees, and consultants to purchase an aggregate of 735,000 shares in the capital of the Company at a price of $0.375 per share, pursuant to the terms of its stock option plan. All of the options are subject to vesting provisions, and any shares issued upon exercise of an option will be subject to a hold period of four months and one day from the date of grant.

Exro Technologies Inc. (CSE: XRO) (OTCQB: EXROF), a Canadian technology company, is an innovative pioneer in the energy sector. Exro has developed and commercialized an electric power module (EPM) that integrates into existing motor systems to make them smarter. Exro’s patented technology optimizes existing motor performance by automatically sensing and adapting operating parameters to an optimized state, creating measurable efficiency gains, reduced mechanical components and increased system availability.

Applications

Exro’s technology and efficiency optimization algorithms improve the performance and efficiency of electric motors by manipulating power delivery to individual coils, thereby enabling the ability to expand operating parameters. This novel approach is scalable and can be utilized in most variable torque applications.

The widespread applications of Exro’s technology apply to optimizing the performance of electric vehicles, locomotive traction applications, industrial motors, and other variable torque applications that benefit from smart energy conversion.

Intellectual Property

Exro’s proprietary, patented software controls electric motor coils through individual coil switching. This introduction of intelligence into energy conversion at the level of individual coils results in expanded speed/torque capability, improved machine efficiency, reliability, safety and maintenance across a wider operating range. Exro’s advanced control algorithms create smart, real-time optimized power management.

Exro currently holds 15 patents, with 8 patents pending and additional patents under development. The company continues to expand its IP portfolio to support its goal of becoming a globally recognized leader in leveraging advanced control algorithms to improve the performance, efficiency and longevity of electric motors and generators.

Market Opportunity

Electric motors are the single biggest consumer of electricity. They account for about two-thirds of industrial power consumption and about 45% of global power consumption, according to an analysis by the International Energy Agency. Exro’s technology seeks to give industries a new way to look at energy—from electric vehicles, to industrial equipment, to renewable applications like wind farms; we are improving the way energy is consumed.

Laboratory Expansion

The 6,500-square-foot Exro Innovation Center (EIC), scheduled to open spring of 2020 in Calgary, will transition the current Victoria lab into one Calgary based center. The company’s new laboratory space will expand its service capabilities to customers, provide larger test capabilities, and showcase how Exro’s technology can be applied to dramatically improve the performance of electrical motors.

The EIC will also host collaborative events to explore advances in energy consumption and electric motor innovations, with participants from across Canada and around the world.

Strategic Partnerships

  • A strategic agreement with Finland’s Aurora Powertrains Oy, which in 2019 released an all-electric production snowmobile called the “eSled,” will see Exro’s technology added to the Aurora electric powertrain. The snowmobile sector’s economic footprint is estimated at $26 billion in the U.S., $8 billion in Canada, and $5 billion in Europe and Asia.
  • An agreement with Potencia in Mexico serving the last mile vehicle segment will integrate Exro’s custom drive and EPM module into small passenger commercial vehicles (taxis) and fleet delivery trucks
  • A licensing agreement with Motorino Electric, a leader in the Canadian electric transportation industry, will integrate Exro’s Electric Power Module technology into Motorino’s CTi electric bicycle.

Management

Chief Executive Officer Sue Ozdemir is a proven leader in the innovation and manufacturing of electric motors. She has nine years of accomplishments at General Electric, acting as CCO and the CEO of GE’s Small Industrial Motors Division, overseeing the division’s North American and international markets – ultimately building the division into a $160 million enterprise.

Chief Commercial Officer Josh Sobil is leading the seamless adoption of Exro’s growing product portfolio focused on the mobility segment and opening doors in all segments including agriculture, heavy industry, energy, construction, among others.

Executive Chairman Mark Godsy is a serial technology entrepreneur who has been involved in many top tier ventures, including two of Canada’s most successful biotech companies.

Exro Technologies Inc. (CSE: XRO) (OTCQB: EXROF), closed Tuesday's trading session at $0.282, up 3.2211%, on 190,715 volume with 67 trades. The average volume for the last 3 months is 128,255 and the stock's 52-week low/high is $0.124389998/$0.522899985.

Recent News

chart

SinglePoint, Inc. (SING)

The QualityStocks Daily Newsletter would like to spotlight SinglePoint, Inc. (SING).

SinglePoint, Inc. (SING) was featured in today's edition of the Cleantech and Climate Change Podcast, talking about today's problems and solutions for the future http://ibn.fm/bVy6q.

SinglePoint, Inc. (SING) is a diversified holding company with operations in multiple industries and verticals including two high-performing market sectors: legal cannabis and cryptocurrencies. SinglePoint has grown from a full-service mobile technology provider to a recognizable brand with a diverse portfolio of undervalued subsidiaries with multiple revenue streams.

SinglePoint is researching opportunities where it can be an active participant by influencing the strategy and direction of high-potential companies whose verified assets offer attractive possibilities for shareholders. The company is guided by a visionary leadership team with extensive experience in technology, engineering, marketing and raising capital.

SinglePoint is bullish on the cannabis industry, bitcoin and blockchain technologies, which is evident in its recent acquisitions and joint-venture announcements. Recent SinglePoint key highlights include:

  • A joint venture with Smart Cannabis Corporation (OTC: SCNA) to license and market Smart Cannabis’ SMART APP. SMART APP enables cannabis growers to measure all aspects of cultivation, from soil nutrient levels to watering cycles and carbon dioxide content in the air. SMART APP will integrate SinglePoint’s bitcoin payment solution to enable growers to process safer and more secure transactions.
  • A joint venture with Global Payout (OTC: GOHE) will build on existing financial technology solutions developed by SinglePoint and Global Payout’s subsidiary MoneyTrac Technology, Inc., to fully optimize the delivery of mobile payment applications for domestic and international organizations.
  • A joint venture with AppSwarm (OTC: SWRM) to start development on a proprietary delivery application that will enable licensed cannabis delivery services and licensed dispensaries to safely make in-home cannabis deliveries.
  • Signed original “Shark Tank” member Kevin Harrington as company spokesman for an innovative, compatible virtual wallet to store any type of cryptocurrency. Harrington recently finished shooting a new national ad campaign featuring SinglePoint and the virtual wallet’s secure method of storing cryptocurrencies.
  • Entered into a letter of intent to acquire 100 percent of Bitcoin Beyond, a premier platform that enables merchants to accept bitcoin payments using existing web-enabled point-of-sale devices.
  • Through SING subsidiary, SingleSeed, the company will soon offer a proprietary cryptocurrency solution that links both cannabis merchants and consumers who seek to take advantage of bitcoin-powered transactions using debit and credit cards. In addition to making bitcoin-backed card purchases possible, the solution enables cannabis dispensaries to digitally track and manage their product inventories, performing tasks like uploading product data, photos and descriptions. The system deducts items automatically from a dispensary’s product listings when a purchase is made. While this fully KYC-AML compliant point-of-sale platform can be utilized for any other retail setting, it will fill a critical need in the underbanked cannabis industry as it continues to seek non-cash payment solutions outside of traditional banking circles.

SinglePoint CEO and founder Greg Lambrecht leads the company in its mission to capture opportunities through an aggressive expansion strategy across a broad range of assets. Lambrecht oversees all company operations including investor relations, leadership of the board of directors, and daily business activities. As the founder of PCI, a leading consumer product distribution company, Lambrecht negotiated agreements with the nation’s largest retail outlets and led PCI through a NASDAQ listed IPO, raising $10 million.

Eric Lofdahl, SinglePoint’s chief technology officer, has more than 20 years of experience in the technology sector including positions in software development, program management, complex system integration and engineering process definition. Prior to SinglePoint, Lofdahl worked at the Boeing Company where he led a team that successfully developed advanced wireless and satellite data products based on commercial technology for the U.S. Air Force.

SinglePoint President Wil Ralston is well known for his successful track record of building and maintaining great relationships with clients. Ralston graduated cum laude from the WP Carey School of Business at Arizona State University with a degree in Global Agribusiness and a specialization in Professional Golf Management. He is currently recognized by the Professional Golfers Association of America (PGA) as a Class A Professional.

SinglePoint, Inc. (SING), closed Tuesday's trading session at $0.008, up 3.8961%, on 2,900,471 volume with 129 trades. The average volume for the last 3 months is 4,242,632 and the stock's 52-week low/high is $0.007/$0.021999999.

Recent News

chart

Sharing Services Global Corporation (SHRG)

The QualityStocks Daily Newsletter would like to spotlight Sharing Services Global Corporation (SHRG).

Sharing Services Global Corporation (OTCQB: SHRG), a diversified holdings company dedicated to elevating the lives of entrepreneurs and clients, announced the release of its newest product called ElevaciTea(TM), available through its subsidiary Elevacity LLC (http://nnw.fm/w11zX). This first-of-its kind, limited edition, vanilla-chai nootropic tea joins the company’s existing lineup of functional beverage offerings. Moreover, SHRG CEO John “JT” Thatch shared that the product’s two-day presale eclipsed all of SHRG’s prior product launches (http://nnw.fm/O9vDu).

Sharing Services Global Corporation (SHRG), formerly Sharing Services Inc., is a diversified company dedicated to maximizing shareholder value, operating through two primary subsidiaries: Elepreneurs Holdings, a direct-selling company, and Elevacity Holdings, a products company. Headquartered in Plano, Texas, SHRG markets and distributes Elevate-branded health and wellness products through an independent sales force of distributors called Elepreneurs.

Proprietary Products

SHRG’s current exclusive Elevate product offerings are marketed under the Elevacity brand, so named to signify the company’s commitment to elevating lives.

The Elevate health and wellness product line consists of nutraceutical products that SHRG refers to as D.O.S.E., which stands for dopamine, oxytocin, serotonin and endorphins – all of which are key hormones proven to promote happiness and well-being.

Elevacity brand products are carefully formulated, chosen and designed to support a single objective: elevate the happiness and well-being of the consumer.

Global Network of Elepreneurs

Elevacity products are shared and sold by a growing international network of home-based entrepreneurs, called Elepreneurs, operated by Elepreneurs Holdings. This SHRG subsidiary provides basic and advanced programs for both new and experienced entrepreneurs who are focusing on their direct-sales careers.

SHRG’s high-performing independent sales force follows the company’s Blue Ocean selling strategy, an approach that encourages individuals to seek new markets, lead, and to “stop competing and start creating.” The Blue Ocean strategy is based on the book, “Blue Ocean Strategy,” written by Professor Renée Mauborgne, who notes that “the lesson here is that the best defense is offense, and the best offense… is to make a blue ocean shift and create your own blue ocean.”

Following this selling strategy, SHRG’s Elepreneurs are taught that, rather than competing directly in a competitive, direct-selling market, they should focus on making competitors irrelevant and succeeding in an uncontested marketplace.

In addition, SHRG’s Elepreneurs use the interactive, video-based VERB sales-marketing platform developed by Verb Technology Company Inc. The app utilizes proprietary interactive video data collection and analysis technology and provides next-generation customer relationship management, lead generation, and video marketing software applications.

Continued Momentum as Industry Leader

These selling strategies have resulted in sharp and consistent revenue gains. In the company’s 10-Q filed with the SEC for the three months ended Oct. 31, 2019, SHRG reported sales of $38.8 million for fiscal Q2 2019, an increase of 116% over sales of $17.9 million reported for the comparable quarter of 2018. Consolidated gross profit jumped by $16.2 million to $27.4 million for the same period compared to Q2 2018.

SHRG’s consolidated operating earnings were $3.9 million in the fiscal quarter ended Oct. 31, 2019, compared to $866,802 for the comparable period the prior year. Consolidated gross margin also grew 70.9% for the three months ended Oct. 31, 2019, compared to 62.2% the prior year.

These numbers are continuing a trend established over the past two years. In fiscal Q1 2019, SHRG achieved revenues of $35.4 million, more than double that of the comparable period in 2018. Even earlier, the company reported sales of $85.9 million for fiscal year ended April 30, 2019. This represents a nine-fold increase, or $77.5 million jump, over the company’s revenues of $8.4 million the prior year.

These numbers bring SHRG’s sales revenues since December 2017 — when the company’s Elevate product line was released — to an impressive cumulative total of $169 million.

Preparing for Success

SHRG is well prepared to continue and accommodate for this growth. The company recently expanded its corporate footprint by moving to a 10,000-square-foot facility in Plano, Texas, that offers ample room to expand as the company grows and flourish. The larger corporate locale provides space for a growing customer service department, product fulfillment, opportunity and training rooms, as well as a video production suite.

In addition, the company has a seasoned, expert leadership team in place, led by John “JT” Thatch. Thatch was appointed president and CEO of SHRG in March 2018, bringing to the company his expertise obtained from successfully starting, owning and operating several businesses in various industries. His experience with corporate growth, acquisitions, financing and negotiation in fast-paced and flexible environments will significantly assist SHRG as the company aims to expand and increase revenues.

Contact
469.304.9400 x 201
Info@SHRGinc.com
http://www.SHRGinc.com

Sharing Services Global Corporation (SHRG), closed Tuesday's trading session at $0.046, even for the day, on 88,538 volume with 15 trades. The average volume for the last 3 months is 348,930 and the stock's 52-week low/high is $0.0215/$0.3944.

Recent News

chart

Predictive Oncology (NASDAQ: POAI)

The QualityStocks Daily Newsletter would like to spotlight Predictive Oncology (POAI).

Predictive Oncology Inc. (NASDAQ: POAI), a leader in the cancer precision-medicine field, has announced the unanimous appointment of its newest board member (http://nnw.fm/TlGT0). Dr. Dan Handley, MS, PhD, brings a wealth of invaluable experience to POAI’s already impressive board of directors.

Predictive Oncology (POAI) is a knowledge-driven precision medicine company focused on applying data and artificial intelligence (AI) to personalized medicine and drug discovery. The company applies its smart tumor profiling and AI platform to extensive genomic and biomarker patient data sets to build predictive models of tumor drug response to improve clinical outcomes for the cancer patients of today and tomorrow. The company has several tools that support its mission of bringing precision medicine to the treatment of cancer.

Through its subsidiaries, Predictive Oncology’s portfolio of assets includes the following:

  • A database of clinically validated historical and outcome data from patient tumors
  • An in-house Clinical Laboratory Improvement Amendments (CLIA)-certified lab
  • A “smart” patient-derived tumor profiling platform
  • An in-house bioinformatics artificial intelligence (AI) platform
  • A new computerized approach growing tumors in the lab to rapidly develop patient specific treatment options
  • An FDA-approved fluid collection and disposal system

Using these resources, and in collaboration with key players in the pharmaceutical, diagnostic and biotech industries Predictive Oncology is working to determine the best pathways for more individualized and effective cancer treatment.

Subsidiaries

Predictive Oncology leverages the synergies of its three wholly owned subsidiaries to bring precision medicine to the diagnosis of cancer.

Helomics applies artificial intelligence to its rich data gathered from the company’s trove of more than 150,000 tumors to personalize cancer therapies for patients as well as drive the development of new targeted therapies in collaborations with pharmaceutical companies. This database, the largest of its kind in the world, is comprised of ovarian, head and neck, colon and pancreas tumors. Helomic’s CLIA-certified lab provides clinical testing that assists oncologists in individualizing patient treatment decisions, by providing an evidence-based roadmap for therapy.

In addition to its proprietary precision oncology platform, Helomics offers boutique CRO services that leverage its TruTumor™ patient-derived tumor models coupled to a wide range of multi-omics assays (genomics, proteomics and biochemical), and an AI-powered proprietary platform (D-CHIP) to provide a tailored solution to its clients’ specific needs.

TumorGenesis is developing a new, rapid approach to growing tumors in the laboratory without the use of rats or mice, allowing for the identification of biomarkers indicative of cancer. This methodology “fools” the tumor into thinking it is still in the body. As a result, the tumor reacts as it naturally would, thereby increasing the accuracy of the biomarker. Once the biomarkers are identified, they can be used in TumorGenesis’ Oncology Capture Technology Platforms which isolate and helps categorize an individual patient’s heterogeneous tumor samples to enable development of patient-specific treatment options.

Skyline Medical’s patented, FDA-cleared STREAMWAY® System is the first true, direct-to-drain fluid disposal system designed specifically for medical applications such as radiology, endoscopy, urology and cystoscopy procedures. The STREAMWAY system is changing the way healthcare facilities collect and dispose of potentially infectious waste fluid by connecting directly to a facility’s plumbing system to automate the collection, measurement and disposal of waste fluids.

The STREAMWAY minimizes human intervention for better safety and improves compliance with Occupational Safety and Health Administration (OSHA) and other regulatory agency safety guidelines. The STREAMWAY eliminates canisters, carts and evacuated bottles, which reduces overhead costs and minimizes environmental impact by helping to eliminate the approximately 50 million potentially disease-infected canisters that go into landfills annually in the United Sates.

Skyline has achieved sales in five of the seven continents through both direct sales and distributor partners.

Competitive Advantage

Precision medicine has become the holy grail of cancer therapeutics. Data driven predictive models of tumors and their responses are critical in both new drug development and individualized patient treatment. The race has begun to model various tumors, which takes 5 to 7 years of clinical evaluation to establish historical and outcome data.

Predictive Oncology enjoys significant competitive advantage. The company already has a vast historical collection of tumors and related data, plus the ability to obtain existing associated outcome data. While others wait for outcome data, Predictive Oncology is in a unique and powerful position, working to deliver the promise of precision medicine to reality. Predictive Oncology already has the clinical data, including how a tumor responded to certain drugs, an in-house bioinformatics AI platform, and only needs to do the tumor sequencing. The significance is underscored by the collaboration with UPMC Magee-Women’s Hospital, designed to reveal which mutations responded to which drug then develop powerful predictive models for future testing and treatment.

Leadership Team

Dr. Carl Schwartz was appointed to Skyline Medical’s board of directors in March 2015 and became interim president and CEO in May 2016. Dr. Schwartz became CEO of Plastics Research Corporation in 1988, leading the company to become the largest manufacturer of structural foam molding products in the U.S. with more than $60 million in revenues and 300 employees by the time he retired in 2001. He holds a bachelor’s degree and DDS degree from the University of Detroit.

CFO Bob Myers has over 30 years of experience in multiple industries focusing on medical device service and manufacturing. He has spent much of his career as a CFO and controller. Myers holds an MBA in Finance from Adelphi University and a BBA in public accounting from Hofstra University.

Gerald Vardzel, President of Helomics, has over 25 years of healthcare executive management experience developing and implementing commercialization strategies and models for technology launches. His Go-To-Market expertise includes equity financing, strategic planning, market intelligence, M&A, and new market development in both start-up and established settings including fortune 500 market leaders. He has developed innovative solutions for both CLIA and FDA regulatory paths defining the delivery chains from discovery to clinical acceptance. Mr. Vardzel also has significant experience designing and implementing sales and marketing programs tailored not only to expand market share, but to empirically assess client satisfaction, strengthen business processes, and maximize profitability. Mr. Vardzel was previously Vice President of Corporate Development and Strategic Initiatives at Global Specimen Solutions. Furthermore, as an executive affiliate to the healthcare industry, he routinely consults for several small-to-mid sized private equity firms advising on, in part, the feasibility of acquisition targets. Mr. Vardzel graduated from the University of Pittsburgh.

Dr. Mark Collins, Chief Information Officer of Helomics, has held multiple executive roles in a variety of discovery, informatics and bioinformatics functions within global pharma, and founded three startup software companies in the machine learning and drug discovery space. In 2001, Dr. Collins worked for Cellomics (now part of Thermo Fisher Scientific), where he played a pivotal role in establishing the High-Content Cell Analysis market, building and commercializing several key informatics and bioinformatics products. After leaving Thermo Fisher, Dr. Collins developed and commercialized informatics solutions for clinical and translational research, specifically in the specimen tracking, omics data management and NGS analysis space, through key roles at BioFortis, Global Specimens Solutions and Genedata. Dr. Collins received his undergraduate degree in Applied Science from the University of Wolverhampton, UK and his Ph.D. in Microbiology from the University of Surrey, UK.

Predictive Oncology (POAI), closed Tuesday's trading session at $2.0999, off by 4.55%, on 213,787 volume with 735 trades. The average volume for the last 3 months is 166,019 and the stock's 52-week low/high is $1.95000004/$8.50.

Recent News

chart

Pressure BioSciences Inc. (PBIO)

The QualityStocks Daily Newsletter would like to spotlight Pressure BioSciences Inc. (PBIO).

Pressure BioSciences Inc. (OTCQB: PBIO), a leader in the development and sale of broadly enabling, pressure-based instruments, consumables, and platform technology solutions to the worldwide biotechnology, biotherapeutics, and other industries, recently announced the opening of their new Ultra Shear Technology(TM) Demonstration Laboratory, located in the company's South Easton, MA facility (http://nnw.fm/5Ic0n).

Pressure BioSciences Inc. (PBIO) develops, markets and sells proprietary laboratory instrumentation and associated consumables to the life sciences sample preparation market. Sample preparation refers to the wide range of activities that precede most forms of scientific analysis. It is often complex and time-consuming, yet a critical part of scientific research. The market for sample preparation products is currently estimated at $6 billion worldwide.

The Company’s product line can be used to exquisitely control the sample preparation process. It is based on a patented, enabling technology platform called pressure cycling technology (“PCT”). PCT uses alternating cycles of hydrostatic pressure between ambient (14.5 psi) and ultra-high levels (up to 100,000 psi) to safely and reproducibly control critical biological processes, such as the lysis (breakage) of cells, the digestion of proteins, and the inactivation of pathogens.

Pressure BioSciences’ product line is led by its newly released, next-generation Barocycler 2320EXTREME instrument. Named a finalist in the prestigious 2017 R&D Awards (also known as the “Oscars of Innovation”), the Barocycler 2320EXT is already being touted by some key opinion leaders as an essential element of the $1.8 billion U.S. “Cancer Moonshot” program. For example, Professor Phil Robinson, Co-head of the cancer research center of the Children’s Medical Research Institute (Sydney, Australia), said in a recent interview: “We are collecting the whole proteome on 70,000 tumor samples from all classes where complete clinical outcome is known. Due to its unique capabilities, the Barocycler 2320EXT has become a critical part of our program. It is the primary enabler of the high-throughput component of the project. Without this step, our project simply could not be done. In fact, the Barocycler 2320EXT works so well we have just purchased two more.”

Momentum is building when it comes to the potential for using the Company’s unique PCT technology platform. Leading scientists are intrigued by Pressure BioSciences’ approach, which among other attributes, revolutionizes the process of rupturing cells (lysis) for further study, yielding superior biomolecules for investigation. The Company’s technology transcends current methods of breaking open cells, which use chemicals, blades, metal beads, or other damaging and altering methods that can ultimately adversely affect the result for researchers. Pressure BioSciences’ PCT technology utilizes customized, controlled hydrostatic (water) pressure to rupture cells in a chamber, enabling exquisitely customized levels of pressure to optimally break open different types of cells at prescribed pressure levels—something never before accomplished in a commercial setting. Using this pioneering method, the result is a truer, more legitimate sample, which boosts the efficacy of research and the quality of results. The potential impact of this technology on scientific advancement is enormous, enabling research scientists to begin their studies with biological samples of unprecedented integrity, with the potential to improve research outcomes at the earliest, most critical step. PCT can additionally inactivate pathogens (e.g., viruses, bacteria) using hydrostatic pressure, making the samples safer to study—another innovation with astronomical potential for application in a variety of markets.

The Company’s high-pressure instruments for research purposes are marketed throughout the United States, Europe, China and Japan. To date, Pressure BioSciences has installed nearly 300 PCT Systems in over 165 leading academic, government, biotech and pharma laboratories around the world. Its primary applications are in biomarker discovery, forensics, agriculture and pathology. Over 100 scientific papers have been published on the advantages of the PCT platform, which is also being used in the specialized fields of drug discovery and design, bio-therapeutics characterization, soil and plant biology, vaccine development and histology.

Impressive as their biotech business is, there is more to the PBI story. Pressure BioSciences recently received two patents in China for its novel Ultra Shear Technology (UST), a process that has potential in a wide range of industrial applications, including extending the shelf life of some food products and making two insoluble liquids (like oil in water) soluble. Patents have also been filed in many other countries worldwide. UST is a novel technique based on the use of intense shear forces generated from ultra-high-pressure valve discharge.

This important technology has the potential to play a significant role in a number of commercially important areas through its ability to create high-quality, stable nanoemulsions. Scientific studies indicate that improved absorption, higher bioavailability, greater stability, lower surfactant levels and other advantages can be achieved with nanoemulsions – all hugely important factors in the fields of nutraceuticals, cosmetics, pharmaceuticals, and in various medical products. There is an enormous opportunity in the cannabis market, since the technology can potentially reduce oil droplets containing cannabidiol (CBD) to nanoparticles, after which they can be safely suspended in a stable water solution—something many companies have endeavored to achieve without success. Researchers looking for a way to increase the bioavailability of cannabinoids in the body will find this technology a game changer.

The Company’s UST technology also has possibilities in the production of clean label foods, which are currently processed using several innovative methods, including high-pressure treatments (such as Starbucks’ Evolution line of juices). In 2015, the worldwide market for high-pressure processed (HPP) food was estimated at U.S. $10 billion. UST uses ultra-high pressures and certain valves to generate intense shear forces under controlled temperature conditions to produce nanoemulsions, and which also significantly reduces food-borne pathogens. Pressure BioSciences’ initial focus with this technology will be to evaluate UST for the production of high-quality dairy products and beverages.

Pressure BioSciences Inc. (PBIO), closed Tuesday's trading session at $1.99, off by 0.50%, on 2,606 volume with 11 trades. The average volume for the last 3 months is 19,701 and the stock's 52-week low/high is $0.600600004/$4.0300002.

Recent News

chart

Plus Products Inc. (CSE: PLUS) (OTC: PLPRF)

The QualityStocks Daily Newsletter would like to spotlight Plus Products Inc. (CSE: PLUS) (OTC: PLPRF).

Plus Products Inc. (CSE: PLUS) (OTCQX: PLPRF) was featured today in a publication from CBDWire, examining how the U.S. cannabidiol industry has been chaotic ever since it was birthed after the 2018 Farm Bill. Although the legislation legalized the cultivation and sale of industrial hemp and its extracts, it didn’t say much more. Aside from defining hemp as cannabis with less than 0.3% THC, the Bill didn’t create a comprehensive regulatory framework for hemp extracts like cannabidiol, and that has been a constant thorn in the CBD industry’s side.

Plus Products Inc. (CSE: PLUS) (OTC: PLPRF) is a branded cannabis-infused products manufacturer of edibles created to support a healthy and active lifestyle. Headquartered in San Mateo, California, PLUS™ concentrates on producing edibles using extracts to ensure compliant, dosable and delicious products that provide a consistent cannabis experience.

First introduced to the market in 2015 to rave reviews, PLUS™ is now one of the top best-selling edible brands in California. PLUS™ operates through a wholly owned subsidiary, Carberry, and has four cannabis-infused gummy candy SKUs (in addition to limited edition SKUs), that are currently sold in over 200 licensed dispensaries and delivery services. All products under the PLUS™ brand are produced in the company’s 12,000-square-foot food-safe cannabis manufacturing facility in Adelanto, California.

PLUS Products shares are currently listed on the Canadian Securities Exchange. PLUS™ raised CAD$20 million through the offering, for which the lead underwriters were PI Financial and Canaccord Genuity. The company intends to use a portion of the IPO proceeds to fund rapid product capacity expansion, factory automation, working capital and new product development.

Operating in the largest adult-use recreational market in the U.S., PLUS Products holds a temporary manufacturing license in California and was one of the first brands to bring fully compliant products to the legal market. California legalized adult use recreational sales on Jan. 1, 2018, and industry analysts expect edible sales there will continue to amass enviable revenues. According to BDS Analytics, edibles made up 18 percent of marijuana retail sales in February 2018 across licensed retailers in California, with PLUS™ products ranking in the Top 10 of edible brands by retail dollar sales.

During the first half of 2018, PLUS Products generated US$2.45 million in sales, a marked improvement over 2017’s US$1.07 million in sales. The company’s established cannabis products are not only compliant with state laws, they are proving to be extremely popular with consumers. Among the PLUS™ product brands are:

  • Blackberry & Lemon RESTORE, an infusion of carefully dosed cannabis with a 9:1 THC to CBD per gummy.
  • Sour Watermelon UPLIFT, a low-calorie gummy crafted from carefully dosed cannabis with an infusion of 5mg THC per gummy.
  • Pineapple & Coconut CBD RELIEF, a tropical flavor gummy made from pure cannabis-derived CBD that is low-calorie, gluten-free and made with kosher ingredients.
  • Sour Blueberry CREATE, a low-calorie gummy infused with hybrid flower containing 5 mg THC.
  • Limited Edition Rose & Vanilla, available at select locations during Winter 2018, these gummies are crafted with 60 mg THC/30 mg CBD per tin.
  • Limited Edition RAINBOW SORBET gummies was created to celebrate Pride during Spring 2018 with a portion of each purchase donated to The Trevor Project, a confidential suicide hotline for LGBT youth.

“We are extremely proud of the products PLUS has brought to market,” remarked Jake Heimark, CEO and cofounder in a statement. “We’ve quickly grown into one of the leading edible brands in California. With the proceeds of this round, we will continue to further our mission: to make cannabis safe and approachable for all types of consumers.”

The PLUS™ team believes that everyone deserves access to consistent, dosable and delicious cannabis products and strives to make that happen. Producing the best infused products at scale requires thoughtful collaboration among experts in many fields. At PLUS™, our team is comprised of Chefs, Chemists, Food Manufacturing Experts, Engineers, Machinists, Visionaries, Creatives, Strategists and others.

Plus Products Inc. (PLPRF), closed Tuesday's trading session at $0.4922, off by 4.7047%, on 47,417 volume with 33 trades. The average volume for the last 3 months is 47,718 and the stock's 52-week low/high is $0.361999988/$4.75.

Recent News

chart

MCTC Holdings Inc. (OTC: MCTC)

The QualityStocks Daily Newsletter would like to spotlight MCTC Holdings Inc. (MCTC).

MCTC Holdings Inc. (OTC: MCTC), a cannabinoid science innovator (dba Cannabis Global), is positioned at the cutting edge of the industry’s trends with its focus on polymeric nanotechnology designed to maximize bioavailability. The company plans to market and license multiple polymeric cannabinoid nanoparticle and nanofiber-based products that will offer enhanced bioavailability and release properties as well as advanced customization options. Also today, the company was featured in the 420 with CNW by CannabisNewsWire. In a report, the Drug Enforcement Administration acknowledged that state-level marijuana legalization minimizes illicit interstate trafficking. The DEA was giving an overview of its enforcement efforts in its performance budget submission to Congress for the 2021 fiscal year.

MCTC Holdings Inc. (OTC: MCTC) is an innovator in the field of cannabinoid nanoparticles and infusion technologies with several important cannabinoid patents filed and an active research and development program underway. The company was reorganized during June of 2019 and announced its intent to enter the cannabis sector and change its corporate identity to Cannabis Global Inc. The company is headquartered in Los Angeles, California.

With the hemp and cannabis industries rapidly expanding in terms of market size, acceptance and number of market participants, MCTC plans to concentrate its efforts on the middle portions of the hemp and cannabis value chain. The company is actively pursuing R&D programs and productization of advanced cannabinoid delivery systems, based on solid polymeric nanoparticles and fibers. These technologies hold the promise to revolutionize the science of cannabinoid bio-enhancement for use in foods, beverages, consumer products and in transdermal applications. Because of nanoparticles’ ability to be quickly absorbed into the bloodstream, nanotechnology has been utilized in the food and drug industry for some time and has the potential for tremendous growth in the cannabis industry (http://nnw.fm/v6RQ6).

Cutting-Edge Technology

MCTC is at the cutting-edge of the cannabis industry’s trends with its emphasis on polymeric nanotechnology. This is not to be confused with the more basic oil-in-water nano-emulsions currently marketed to the food and beverage industry. The company’s polymer-based particles offer significant loading of active ingredients and unmatched flexibility and customization, allowing for myriad combinations of cannabinoids with unique performance characteristics. MCTC believes polymeric nanotechnology particles will be a critical technology area for the cannabinoid formulation marketplace.

The company continues to build its R&D program, specifically researching the development of improving methods to make cannabinoids available to living systems. Instrumental in the research program is the development of novel polymeric nanoparticles and nanofibers. These have the potential to elevate the potential of cannabinoid products in the following ways (http://nnw.fm/cK3Bl):

  • Significantly improving bioavailability
  • Allowing for ultra-high loading rates
  • Enhancing customization of cannabinoid combinations
  • Improved dosing precision
  • Providing more control in release parameters

MCTC leadership understands the importance of developing intellectual property (IP) in the ever-evolving cannabis industry. A recent Forbes article described IP as “critical for creating true differentiation between companies and their product and service offerings” (http://nnw.fm/57Fjh). Recognizing the importance of IP, MCTC has been consistent in its application for patents to protect its innovative nanotechnology applications.

Patents

MCTC has now filed four patents on its cannabinoid delivery technology systems:

  • The company first collaborated with Cannabis Nanosciences Inc. on technologies. This became the basis for its first patent filing on an innovative edible dissolvable film for cannabinoid ingestion.
  • Its second patent filing for cannabinoid nanoparticles combined TPGS, a water-soluble form of vitamin E.
  • Its third patent filing involved a unique 4th dimension, 3D printed cannabinoid delivery system for beverages.
  • Its fourth patent, considered its most significant, broadly covers many aspects of nanoparticles and nano fibers comprising one or more cannabinoids disposed at least partially within a water-soluble medium.

Collaborations

MCTC collaborated with Marijuana Company Inc. (OTCQB: MCOA) subsidiary hempSmart Inc., under a hemp extract and CBD product supply agreement wherein hempSmart will utilize its extensive network of marketing partners to market MCTC’s powered drink mixes and other CBD edibles online. These products are designed for the dry beverage and edibles sector and will be supplied by MCTC. They incorporate the company’s patent-pending cannabinoid infusion technologies and will be trademarked as Hemp You Can Feel (TM) and Gummies You Can Feel (TM).

Leadership

MCTC CEO and chairman Arman Tabatabaei boasts 15 years of management and operations experience and is considered an expert at data collection and analysis relative to resource management, risk forecasting, and profit and loss management. He has acted as a consultant with Cannabis Strategic Ventures (OTCQB: NUGS) and played an instrumental role in improving operations at Sugarmade Inc. (OTCQB: SGMD) relative to the company’s hydroponic growth supplies initiatives.

MCTC founder and director Robert Hymers also brings a seasoned perspective, having had significant experiences in the cannabis industry and as a financial executive and consultant. He is the managing partner of Pinnacle Tax Services in Los Angeles and was previously CFO and director of Marijuana Company of America Inc. (OTC: MCOA). He is currently a member of the Strategic Advisory Board at Massroots Inc. and acts as a consultant to both Cannabis Strategic Ventures Inc. and Sugarmade Inc. Hymers’ background in tax accounting, auditing, SEC reporting, mergers and acquisitions, and corporate finance has immense value in his current position at MCTC Holdings.

MCTC Holdings Inc. (MCTC), closed Tuesday's trading session at $0.23575, off by 0.031803%, on 238 volume with 3 trades. The average volume for the last 3 months is 15,952 and the stock's 52-week low/high is $0.05/$3.00.

Recent News

chart

Lexaria Bioscience Corp. (CSE: LXX) (OTC: LXRP)

The QualityStocks Daily Newsletter would like to spotlight Lexaria Bioscience Corp. (LXRP).

Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) was featured today in a publication from HempWireNews, examining how it will definitely take a while before the U.S. cannabis sector settles even if some states were already allowing medical cannabis within their borders before the 2018 Farm Bill liberated hemp from decades of prohibition. Defining hemp as cannabis with less than 0.3% THC, the legislation allowed growers to farm hemp under state or tribal programs.

Lexaria Bioscience Corp. (CSE: LXX) (OTC: LXRP) has developed and out-licenses its proprietary DehydraTECH™ technology for improved taste, rapidity and delivery of bioactive compounds, including nicotine and cannabinoids. To achieve higher absorption rates and fast onset, consumers traditionally defaulted to smoking. Lexaria provides a superior administration method by delivering these substances through a patented process within edible food products, thus eliminating all the harmful health consequences of smoking.

Lexaria’s technology is unique in that it takes advantage of GRAS (Generally Recognized As Safe) food ingredients processed with its patented DehydraTECH technology to improve taste, remove odor and decrease the time to onset of bitter-tasting drugs. Lexaria is primarily a B2B enterprise and has existing cannabinoid licensing agreements with companies in Canada and the United States. Lexaria has also developed its own hemp-oil brands partly for demonstration purposes, utilizing its patented technology to infuse hemp oil ingredients within popular foods such as coffee, tea and supplements. These brands include ViPova™, TurboCBD™ and ChargD+™.

Virtually unique across both the hemp and the cannabis industries, Lexaria has successfully entered into a R&D and product development partnership with one of the largest cigarette companies in the world for oral forms of nicotine delivery. Only a small handful of hemp or cannabis-related companies have achieved formal relationships with Fortune 500 industry leaders, demonstrating the wide applicability of Lexaria’s technology.

In June 2019, building on its original 2015 independent, third-party laboratory in vitro lab experiments, which confirmed the absorption levels of cannabidiol (“CBD”) into human intestinal cells rose by 499% through the utilization of the DehydraTECH technology, Lexaria completed a series of animal studies using an enhanced formulation of its DehydraTECH technology. The results of the animal studies using the enhanced DehydraTECH formulation showed an increase of CBD delivery into the blood when compared to generic industry MCT coconut-oil formulations by 811%. In addition, the animal studies also showed delivery of 1,937% more CBD into animal brain tissue after 8 hours using the enhanced DehydraTECH technology when compared to generic industry MCT coconut-oil formulations.

Lexaria also has completed the first phases of its collaborative research program with the Canadian government’s National Research Council (the “NRC”) under which several studies were designed to optimize Lexaria’s DehydraTECH technology, enabling delivery of API’s within foods, beverages, capsules and other ingestible formats. These studies investigated the lipophilic active agent classes including cannabinoids, vitamins, NSAIDs and nicotine using advanced analytical techniques, including mass spectrometry and nuclear magnetic resonance testing, with the results of the studies confirming that Lexaria’s DehydraTECH technology did not create any covalent-bonded new molecular entity (“NME”). Whenever an NME is created, regulatory bodies such as FDA and Health Canada routinely require extensive health, safety and efficacy studies prior to that product’s release into the marketplace. That the NRC program failed to find evidence of an NME suggests products utilizing the DehydraTECH technology may require a less burdensome regulatory pathway.

Results from this R&D have helped support B2B relationships with Fortune 500 companies. Lexaria has four distinct subsidiaries that focus on different market sectors: hemp/CBD; pharmaceutical; cannabis; and nicotine. In August 2019, Lexaria was issued its cannabis research and development licence from Health Canada which will allow Lexaria to continue its further investigations in-house of its DehydraTECH technology in connection with cannabinoids, along with ongoing work with vitamins, NSAIDs, PDE5-inhibitors, nicotine and other molecules.

Aside from testing, a critical component of Lexaria Bioscience’s business model is a strong and growing intellectual property portfolio. As of the August 2019, the company’s patent portfolio includes ~60 patent applications filed and pending in more than 40 countries around the world; and 16 patents granted to date. Lexaria is expecting additional new patent awards both in the U.S. and internationally by the end of 2019 and beyond. Some of its more recent areas of investigation have included human hormones and erectile dysfunction substances, among others. Lexaria’s granted patent portfolio related to cannabinoid delivery is one of the largest in the world.

Royalties play a vital role in Lexaria’s revenue-generating business model. The company out-licenses its technology to third-partners and has signed licensing agreements with start-up companies as well as with a Fortune 100 industry leader. The company’s growth initiatives are guided by a management team headed by CEO Chris Bunka, a serial entrepreneur who has contributed to several multi-hundred million-dollar valuations over the course of his career. He is supported by a growing team of professionals with extensive experience in pharmaceutical and bioscience sectors, invention, toxicology, consumer goods and other relevant skillsets.

Lexaria Bioscience Corp. (LXRP), closed Tuesday's trading session at $0.3656, up 11.9481%, on 61,941 volume with 41 trades. The average volume for the last 3 months is 104,742 and the stock's 52-week low/high is $0.3037/$1.34000003.

Recent News

chart

The Green Organic Dutchman (TSX: TGOD) (OTC: TGODF)

The QualityStocks Daily Newsletter would like to spotlight The Green Organic Dutchman (OTC: TGODF).

The Green Organic Dutchman Holdings Ltd. (TSX: TGOD) (US: TGODF), a leading producer of premium certified organic cannabis, reports its results for the fourth quarter and fiscal year ended December 31, 2019. These filings are available for review on the Company's SEDAR profile at www.sedar.com.

The Green Organic Dutchman (TSX: TGOD) (OTC: TGODF), whose principal location is in Hamilton, Ontario, produces farm grown, organic, pesticide-free medical cannabis in small batches using all natural, organic craft growing principles. TGOD is licensed under the Access to Cannabis for Medical Purposes Regulations (ACMPR) to cultivate medical cannabis. The company carries out its principal activities producing cannabis pursuant to the provisions of the ACMPR and the Controlled Drugs and Substances Act (Canada).

Committed to becoming the global leader in delivering organic cannabis solutions that enhance people’s lives, TGOD consistently adheres to the highest levels of excellence. Its world-class management team includes a proven group of leaders with outstanding executive and operational experience specific to consumer packaged goods, consumer products, cannabis and finance industries.

TGOD is positioned as one of the highest quality and most cost efficient cannabis producers in Canada by leveraging innovative technology and low-cost power solutions. It holds one of the largest land packages under a single ACMPR license in Canada, providing future cannabis Agri-park style development and opportunities for joint ventures, licensing and distribution partners. Its industry leading alliance partners include Eaton, Ledcor Group and Hamilton Utilities Corp.

Eaton is the second largest power management company in the world and promises to supply innovative and cost effective power solutions to meet TGOD’s growing demands. Construction management is supplied by Ledcor, Canada’s second largest multidisciplinary construction company and a pioneer in the Green Building Industry. An alliance with Hamilton Utilities Corp allows TGOD to reduce its power costs from $0.13 per kWh to less than $0.05 per kWh. Greenhouse design is provided by Larssen Greenhouse, whose 25-plus years of experience in building some of the most modern and sophisticated greenhouses in the industry will provide TGOD with state of the art, climate-controlled hybrid greenhouse solutions.

Canada is quickly becoming a hub for cannabis investors with over $1.3 billion raised by Canadian companies to date. There are 58 licensed producers to service a population of 36 million and only two organic producers. TGOD, which holds licenses in Ontario and Quebec, is strategically located in both provinces that together claim 22 million Canadians as residents. Another estimated 57 million people live next door in six U.S. bordering states.

The Canadian cannabis market currently has a massive supply demand gap, which makes TGOD’s expansion plans even more important to investors. These plans include a combined build-out capacity of 970,000 square feet, allowing TGOD to produce 116,000 kg annually of organic cannabis. Upon completion, Phase One in Hamilton, Ontario, which is fully funded, will provide 150,000 square feet of growing capacity capable of producing up to 14,000 kg of cannabis or $112 million in revenue at $8 a gram.

The company’s Quebec expansion will be constructed on a recently secured 75-acre property near Montreal. This new property has a planned expansion of 820,000 square feet capable of producing 102,000 kg of organic cannabis. The first phase of this expansion is underway and construction is expected to be completed by the end of 2018. Quebec’s first phase will consist of 220,000 square feet capable of producing 22,000 kg of cannabis. Two additional expansion phases will add 250,000 square feet (26,000 kg of cannabis) and 350,000 square feet (54,000 kg of cannabis). Power costs remain exceptionally low for both facilities with access to all other needed utilities available and close by.

TGOD also plans to gain a share of the burgeoning cannabis oils market which by Q1 2017 accounted for 49 percent of all cannabis sold in Canada under the ACMPR, up from only 27% in Q2 2016. TGOD has ordered a purpose-built extraction laboratory with an estimated commission in Q4 of 2017. This is a commercial-scale CO2 extraction unit capable of processing up to 12,000 kg of raw material per year and producing approximately $170 million worth of organic cannabis oils. Raw cannabis oil provides a significant downstream manufacturing opportunity into several potential recreational market verticals including edibles, beverages, topicals and concentrates.

Data from the Canadian ACMPR Market Trends report indicates a rising number of consumers will continue to seek out healthier, less conspicuous ways to consume cannabis, ensuring sales of organic cannabis oil products remain brisk. Organic cannabis products demand a significant premium compared to non-organic products and the demand keeps growing.

Plans to take the company public are underway with an initial public offering (IPO) slated for January 2018. In November, the company raised $13 million in equity financing and in March closed a $27 million non-brokered private placement. Another $20 million is currently being raised before the IPO in January, which will be utilized for expansion plans.

TGOD is uniquely positioned between the medical and recreational cannabis industry since Canada is scheduled to legalize cannabis for all adults in mid-2018. As of August 2017, TGOD has 2,400 shareholders. Established in 2012, TGOD’s motto, “Making Life Better,” can be seen in its strategic partnerships, top quality management team, and dedication to organic farming and principles.

To learn more about the company and how to invest, contact TGOD directly at financing@tgod.ca

The Green Organic Dutchman (OTC: TGODF), closed Tuesday's trading session at $0.31, up 0.226317%, on 1,286,703 volume with 601 trades. The average volume for the last 3 months is 1,026,549 and the stock's 52-week low/high is $0.250099986/$4.38000011.

Recent News

chart

GP Solutions (OTC: GWPD)

The QualityStocks Daily Newsletter would like to spotlight GP Solutions (GWPD).

Micro Lab Farms, a premier provider of automated indoor micro-farms, announced a new program to allow entrepreneurs to rapidly enter Oklahoma's fast-growing cannabis industry. The New York Times recently reported that entrepreneurs are flocking to Oklahoma to enter the cannabis industry. A combination of factors, including low taxes and licensing fees, and few regulations, have created the perfect environment for cannabis businesses. Micro Lab Farms offers turnkey systems that make it easy for virtually anyone to start growing cannabis. The company offers GrowPods, designed by GP Solutions (OTC:GWPD).

GP Solutions (OTC: GWPD) is developing scalable farming systems for soil-less indoor organic farming. The company’s GrowPods are automated micro-farms that use hydroponic technology and unique soil systems to cultivate the highest-quality specialty leaf crops. The system is designed and engineered for ease of use, allowing users to farm year-round in any location of the world, supporting the company’s mission to provide customers with the ability to cultivate their own organic “superfoods.”

GrowPod Design & Function

GrowPod is a modular, stackable and mobile vertical growing environment specifically engineered to maximize yield and automation. GrowPods are available as a vertical pod, stacker pod or custom-built pod.

The Stacker Pod is a certified organic soil system that offers growers multiple levels of planting in order to maximize space and produce options with different fruits and vegetables. The Vertical Pod utilizes a vertical hydroponic system. It is affordable, scalable, efficient, automated and sustainable. The output provides customers with fresh and clean produce year-round in any climate. The Custom Pod is built to suit the farmer’s specific crop and grow goals.

Each 320-square-foot GrowPod container will have an annual production capability of up to four times that of outdoor growing methods, dramatically increasing profitability to the grower. The controlled environment of the GrowPod ensures efficient power and water usage in growing a wide range of horticultural and agricultural products in all environments and climates.

Thanks to a combination of hydroponic and certified organic soil systems, crop yields are higher, faster, and more consistent that conventional means. Customers can enjoy an average of eight higher yield crop cycles anywhere in the world.

GrowPod Features:

  • Modular, stackable and mobile
  • Fully insulated, food-grade shipping container
  • Engineered for automation
  • Efficient LED lighting
  • Hydroponic or soil-based platforms
  • Proprietary air and water filtration
  • Climate-controlled
  • Remote monitoring

GP Solutions also offers many services to its customers, including:

  • Shipment and installation service of its shipping container farms
  • On-site training
  • Provision of custom planting and harvesting schedule
  • Provision of growing supplies, seeds, nutrients, packaging, branding and repair materials
  • On-site visits, on-call and scheduled maintenance, and re-supply
  • Remote monitoring and automated control of environmental nutrients, environmental growth factors (PH, temperature, light) and circulation
  • Technical assistance
  • Consulting and custom facility systems design

Competitive Advantage

GrowPods allow cultivation to take place year-round, which maximizes ROI. The systems are sealed from outside pathogens, contaminants, pesticides, and the result is clean and robust crop production.

GP Solutions also has a line of remarkable new proprietary soil mixtures and nutrient lines which contain no animal products. These products are vital, as many other soils and additives can contain harmful pathogens and contaminants that can cause crops to become tainted or fail rigorous testing.

Global Solution

GP Solutions has partnered with the world’s leading food nonprofit companies, including Feeding America, Seeds of Hope, Habitat for Humanity, Meals on Wheels America, L.A. Kitchen, and Farm Bread, to help insecure communities take control of their own food dependence using container farms.

GP Solutions (GWPD), closed Tuesday's trading session at $0.55, even for the day, on 900 volume. The average volume for the last 3 months is 397 and the stock's 52-week low/high is $0.589999973/$21.00.

Recent News

chart

Wonderfilm Media Corporation (TSXV: WNDR) (OTC: WDRFF)

The QualityStocks Daily Newsletter would like to spotlight Wonderfilm Media Corporation (OTC: WDRFF).

Wonderfilm Media Corporation (TSX.V: WNDR) (OTCQB: WDRFF) on Monday announced that, effective March 9, 2020, Norman Tsui has resigned as its executive vice president, interim chief financial officer, corporate secretary and as a director of the Company. As a result, Wonderfilm is working to identify suitable candidates to replace Tsui. The Company thanks Mr. Tsui for his contributions, especially with regard to stepping in as the interim chief financial officer and working to resolve the Cease Trade Order against the Company, and wishes him well in his future endeavors. To view the full press release, visit http://nnw.fm/9dtLD

Wonderfilm Media Corporation (TSXV: WNDR) (OTC: WDRFF) main business is the worldwide production of high-quality feature films and episodic television. The Wonder?lm team includes Hollywood veterans who have packaged, produced and delivered several profitable recent films, including “BlacKkKlansman,” “Get Out” and “The Hurt Locker.” Having these individuals on the Wonderfilm team demonstrates the company’s proven access to Academy Award-quality films and upside.

Wonder?lm maintains a continuing $58 million annual production slate to meet the constant and growing need for content worldwide. The company’s risk-averse production process results in predictable and consistent revenue streams.

Soaring demand for content from streaming providers is fueling industry growth. The global media and entertainment market is expected to grow from $1.9 trillion in 2017 to $2.4 trillion in 2022, a five-year CAGR of 4.4%.

The company recently formed Wonderfilm Global, an international film and television sales and distribution joint venture that is expected to generate significant incremental revenue.

Wonderfilm has strong relationships throughout the entertainment industry, which enables cost-effective production budgets and in-demand content creation.

Management Team with Proven Track Records

Kirk Shaw: Over 240 movies and seven television series to his credit. Headed up Canada’s largest independent film and television production company, attaining $100 million revenue two years straight with 8% EBITDA.

Dan Grodnik: Founded Mass Hysteria Entertainment, a publicly traded company, and became its chairman/CEO. Produced over 50 feature films, including “Bobby,” the 2006 Robert Kennedy biographic film.

Shaun Redick & Yvette Yates: $300 million+ USD total production budgets to date with a combined 175 award wins/355 nominations, including 10 Oscar nominations. In 2017 and 2018, they produced two of the most successful Hollywood films of those years: “Get Out” ($255 million USD gross revenue) and “BlacKkKlansman” ($100 million USD gross revenue). Scheduled to produce two to three films per year for Wonderfilm, with the first release slated for October 2020. Committed to the 4% challenge to give more women and women of color the opportunity to direct.

Jeff Bowler: 2017 Emmy Award-winning producer. Vice president of acquisitions and production for The Exchange, one of the top film sales and finance companies in the world. Bowler is the executive for Wonderfilm Global distribution.

Bret Saxon: Through his company, TMP Inc., Saxon created M&A deals worth over US$750 million across 113 countries. Produced several feature films and made-for-television movies, including Wonderfilm’s 2019 movie “Zombie Tidal Wave” for NBC/Universal’s SYFY.

17-Title Movie Slate — Greenlit

Wonderfilm currently has 17 films greenlit with combined budgets totaling $58 million. Wonderfilm production stars include: John Travolta, Nicolas Cage, Guy Pearce, Ryan Phillippe and Anne Heche, to name a few.

Some of the company’s most notable greenlit projects include the horror film “Amityville 1974,” slated for theatrical release in October 2020, and the action film “Inside Game” starring Tyrese Gibson, which will be released to theaters in fall 2020.

The company is also actively developing a number of other new IP projects, including a dramatic biographic feature titled “Life and Times of Steve McQueen,” a film adaptation of the bestselling novel “Merchant of Death” and a television series headed by “CSI: Crime Scene Investigation” creator Anthony Zuiker.

 

Potential for Breakout Success

Wonderfilm movies have the potential for millions of dollars in revenue from the kind of breakout success generated by films like “Saw” and “Get Out,” which would propel Wonderfilm and its revenue streams to a new level. Wonderfilm has several potential breakout films in its development/production queue.

Note: Potential breakout films are not factored into company’s revenue projections.

Base Hits and Home Runs

In tandem with its slate of high-profile films, Wonder?lm continues to finance, produce and deliver many profitable low-risk, lower-budget films that are base hits. Shaun Redick is a home run hitter, and his upcoming Wonderfilm projects are anticipated to be home run hits for the company, while base hits such as “Zombie Tidal Wave” provide a consistent source of revenue.

Recent Industry Breakout Films Include:

  • SAW – $1.2 million budget = $103.9 million in sales
  • Pulp Fiction – $8 million budget = $212 million in sales
  • My Big Fat Greek Wedding – $5 million budget = $250 million in sales
  • Lost in Translation – $4 million budget = $120 million in sales
  • Get Out – $4.5 million budget = $255.5 million sales (Shaun Redick)

Note: Revenue from most of Wonderfilm’s current slate will be recorded on the books in 2020 or 2021.

Recent Wonderfilm Releases

  • Aug. 17, 2019: Co-produced with NBC/Universal, “Zombie Tidal Wave” premièred on the SYFY channel to strong ratings.
  • Aug. 29, 2019: “The Fanatic” starring John Travolta opens in U.S. theaters.
  • Sept. 5, 2019: “Tammy’s Always Dying” premiers at Toronto Film Festival.
  • Nov. 8, 2019: “Primal” starring Nicolas Cage opens in U.S. theaters.

Wonderfilm Global Distribution

At the 2019 Cannes Film Festival, Wonderfilm officially launched Wonderfilm Global, a new film, television and media foreign sales/distribution joint venture with 101 Films and Paul McGowan.

Wonderfilm acquired 51% ownership in the joint venture structure and immediately began attaching its own productions to Wonderfilm Global. The joint venture represents a significant opportunity for Wonderfilm, changing how the company does business.

The intention behind Wonderfilm Global is to keep distribution margins in-house that previously went to other companies. Since most Wonderfilm movies are relatively low-risk and easy to sell because they feature desirable cast and genre, third-party distribution companies were previously earning approximately 10%, plus expenses, on Wonderfilm movies without any level of risk. Now, revenue is generated through presales of Wonder?lm projects and, at times, third-party films. The average Wonder?lm movie is pre-sold for $5million, garnering $500,000 to $750,000 per sale as a commission. These commissions now stay in-house with Wonder?lm Global, and the company expects to sell 10 to 12 third-party films between fall 2019 and fall 2020, generating roughly $6 million in commission income.

A further revenue source is generated from theatrical sales through a 50/50 upside split once the minimum sales threshold is met.

Wonder?lm Global has offices in Vancouver, Beverly Hills, London, Ireland, Seoul and China.

Wonderfilm Business Model

Wonderfilm productions are structured to begin generating a return to the company as soon as the camera starts rolling.

Return Before a Film is Delivered: Producer fee line items are included in each production budget. These range from $50,000 to $500,000, depending on the total budget, and are paid to Wonderfilm most commonly on the first day of principle photography.

Distribution: Wonderfilm Global charges sales and distribution fees within each production budget to cover its presale costs.

Note: Wonderfilm’s productions are all structured to minimize risk by matching budget to funds available.

Return After a Film is Delivered: Unsold presale territories are countries or territories left off of a film’s presale list, either for strategic reasons or because the broadcaster/distributor is waiting to see the completed film. These outside-the-budget distribution sales become Wonderfilm profit centers.

Sales overages once contracted presale threshold is surpassed.

The company’s film library grows with each new production, adding to future sales revenue. Depending on the agreement, exploitation rights for future worldwide sales return to Wonderfilm four or seven years after delivery. As of October 2019, Wonderfilm’s growing film library comprises 18 titles for future exploitation.

Note: The nature of the film business is that box office revenue lags production up to a couple of years.

$50 Million Wonderfilm Production Fund (WPF):

Wonderfilm is in the process of raising $50 million to establish a Wonderfilm Production Fund (WPF). WPF is designed to consolidate traditional production financing models into a single diversified, asset-backed debt instrument.

The WPF is a highly specialized investment vehicle with noncorrelated market returns normally reserved for institutional banks and specialty lenders, and it would pay 8% interest directly from each Wonderfilm movie or series budget and not from corporate funds. These same interest payments are already added to each production budget, as the company currently closes a separate financing for every film. The WPF would significantly streamline Wonderfilm’s production rate, adding revenue more quickly and broadening the yearly production slate.

For fund investors, the WPF is a dedicated production-financing vehicle designed to offer a risk-moderated approach to investing in film finance. The managed process provides structure and reassurance that are normally experienced only when working with an institutional lender that has a dedicated staff and resources.

All projects being financed are for Wonderfilm productions, with the fund collateral fully secured by receivables, including presale contracts, government incentives, or a guarantee from Wonderfilm for any unsecured amounts as may be permitted.

Wonderfilm Media Corporation (OTC: WDRFF), closed Tuesday's trading session at $0.075, off by 31.8182%, on 1,700 volume with 1 trade. The average volume for the last 3 months is 37,621 and the stock's 52-week low/high is $0.07/$0.27000001.

Recent News

chart

Marijuana Company of America Inc. (MCOA)

The QualityStocks Daily Newsletter would like to spotlight Marijuana Company of America Inc. (MCOA).

Marijuana Company of America Inc. (MCOA) was featured today in a publication from CBDWire, examining how the company’s strategic partner, MCTC Holdings Inc. (OTC: MCTC), a cannabinoid science innovator (dba Cannabis Global), is positioned at the cutting edge of the industry’s trends with its focus on polymeric nanotechnology designed to maximize bioavailability.

Marijuana Company of America Inc. (OTC: MCOA) (the “Company”) are pioneers in the cannabis industry going back to 2009 when Don Steinberg, MCOA’s CEO, founded the first marijuana company ever to trade on a U.S. stock market, Medical Marijuana Inc. Since then, Don and his partner, Charlie Larsen, have formed Global Hemp Group and Marijuana Company of America. They have experienced the shift of legislation first hand, not only for the legalization of marijuana but also the emerging hemp-based CBD products.

The CBD market is growing exponentially and consequently the founders of MCOA have constructed their business model around the development of industrial hemp-based CBD products. The industrial hemp plant can be used to produce products that are carbon neutral or even carbon negative. It is one of the longest, strongest natural fibers on earth, used as a building material that is free of mold, pesticide-resistant, and fire proof. Hemp has also been described as a “super food,” which provides additional business opportunities. No part of the plant is left unused and the Company’s overall strategy is to take advantage of every profit center from farm to the multiple valuable finished products.

The cannabis and hemp industries are experiencing unprecedented growth that is expected to continue for many years as these industries are now accepted globally and continue to mature and expand. North American consumers spent $6.7 billion on legal cannabis products in 2016, up 34% from 2015’s $5 billion. This trend is widely expected to explode at a 27% compounded annual growth rate to reach $22.6 billion by 2021, according to ArcView Market Research.

The company offers investors the opportunity to be on the forefront of cannabis and hemp innovation through cultivation, processing in the legal cannabis and industrial hemp sectors. The Company’s business model includes producing a diverse portfolio of synergistic business segments that provide value to its shareholders. Its vertically integrated business model and distribution platforms are positioned to capture market share by developing recognizable and valuable brands.

Under the MCOA umbrella, wholly owned subsidiary hempSMART™, Inc. is committed to bringing high quality CBD-based products to the market through its affiliate marketing program. Through hempSMART, MCOA’s strategic approach to the distribution of products is through a networking architecture geared to maintain customer loyalty and capture market share. The patent-pending product “hempSMART Brain,” is designed to revolutionize the safe and effective support of healthy brain function. The brand new product, HempSMART DROPS, is a full-spectrum CBD tincture formulated with hemp and fractionated coconut oils. The hempSMART marketing team has decades of experience, and is well positioned to take the hempSMART brand to a global audience.

Marijuana Company of America Inc. (MCOA), closed Tuesday's trading session at $0.025, off by 21.875%, on 1,059,361 volume with 144 trades. The average volume for the last 3 months is 1,184,181 and the stock's 52-week low/high is $0.015499999/$1.13999998.

Recent News

chart

SRAX Inc. (NASDAQ: SRAX)

The QualityStocks Daily Newsletter would like to spotlight SRAX Inc. (NASDAQ: SRAX).

SRAX Inc.'s (NASDAQ: SRAX) is a digital marketing and consumer data management technology company. SRAX’s technology unlocks data to reveal brands’ core consumers and their characteristics across marketing channels.

Through its BIGtoken platform, SRAX has developed a consumer-managed data marketplace where people can own and earn from their data, thereby providing everyone in the internet ecosystem choice, transparency and compensation.

SRAX’s tools deliver a digital competitive advantage for brands in the CPG, automotive, investor relations, luxury and lifestyle verticals by integrating all aspects of the advertising experience, including verified consumer participation, into one platform.

SRAX Verticals

  • SRAX Core: SRAX Core is a custom digital media management platform that enables brands and agencies to surpass the challenges of omnichannel marketing campaigns. It offers one comprehensive dashboard to manage digital media campaigns, inventory and reporting.
  • SRAX Social: SRAX Social is a free social media management tool that makes it easy for brands, agencies and individuals to grow their digital presence. It offers free and unlimited users, Facebook auto boosting, and a custom analytics dashboard. Its managed services team can also build and execute marketing plans for your unique specific needs.
  • SRAX IR: SRAX IR unlocks stock buyers’ behaviors and trends for issuers of publicly traded companies. The platform provides insights on shareholders and market makers, investor relations management, shareholder outreach tools and data-driven marketing.
  • SRAX Auto: SRAX Auto unlocks auto intenders’ data to create measurable connected experiences on the road to purchase. It offers proprietary auto intender profiles, multi touchpoint communication and custom location-based ads.
  • SRAX Shopper: SRAX Shopper delivers a cross channel, premium digital experience at scale to high value shopper audiences. It offers proprietary shopper profiles, cost per click pricing, and custom text and add to cart ad units.
  • SRAX Lux: Launched in June 2019, the SRAX Lux platform targets and reaches luxury consumers at luxury retail stores, high-end art, music, film, fashion and sports events, across all consumer devices.

BIGtoken

BIGtoken, available for download on the App Store and Google Play, revolutionizes data collection. BIGtoken is a platform that creates a secure and transparent environment for consumers to own and earn from their data. To date, there are 15.9 million BIGtoken registered users worldwide.

The optimization and monetization of data is a multibillion-dollar business. Worldwide spending on big data and business analytics solutions reached $166 billion in 2018 and is projected to surge to $260 billion by 2022. BIGtoken’s consumer vision is committed to delivering choice, transparency and compensation to the individual.

Through BIGtoken, consumers earn rewards when they opt into sharing their data and when that data is purchased. Consumers decide what data is shared, who can buy it and how it’s used, and advertisers reach real, responsive audiences. The benefit of this is two-fold: consumers know how their data is used and advertisers gain verified consumer data for targeting.

Users of the BIGtoken app can officially be paid in cash or gift cards in exchange for giving brands access to their anonymized data, answering questions, checking into locations, recruiting new members, and more. Users can deposit their earnings directly into PayPal accounts or be paid through gift cards from favorite retailers such as Walmart.

SRAX has also partnered with several high-profile, nonprofit associations to provide BIGtoken users the ability to donate their earnings. Partnerships include the American Heart Association, dedicated to fighting heart disease and stroke; HealthCorps, which helps high school students make better choices about health and physical fitness; and the ALS Association, which recently launched its Challenge Me campaign.

International Expansion

BIGtoken is formally launching into several international markets and partnering to foster local support. SRAX recently signed a joint venture with the Yash Birla Group to launch BIGtoken in India. Based in Mumbai, the Yash Birla Group, one of India’s largest conglomerates, has diversified interests in consumer and industrial products.

The partnership will bring BIGtoken’s platform to India, which has a digital population of 627 million. The India digital advertising market is $3.6 billion and is set to grow at a compound annual growth rate of 32%, making it one of the largest growing digital ad markets in the world.

SRAX Mexico is led by Moe Avitia, who has more than 18 years of experience in business development and building high-tech teams. SRAX Mexico includes a team of 90 employees, including 70 engineers.

BIGtoken Europe is currently evaluating data centers in individual countries for privacy laws.

Leadership

Christopher Miglino is CEO and founder of SRAX. He has spent the past 20 years working in the digital advertising space and has successfully launched and sold two internet companies. Both of these companies were sold to publicly traded companies on the NASDAQ. He has a detailed understanding of how technology interacts with brands.

Kristoffer Nelson is COO of SRAX and a founding member of BIGtoken. With over 15 years of technology and creative business experience, Nelson has been a guest speaker for Loyola Marymount University among other academic institutions, the National Association of Broadcasters, the IAB and numerous other professional and media organizations.

SRAX Inc. (NASDAQ: SRAX), closed Tuesday's trading session at $2.55, up 19.1589%, on 72,954 volume with 408 trades. The average volume for the last 3 months is 90,480 and the stock's 52-week low/high is $1.04999995/$5.8499999.

Recent News

chart

The QualityStocks Numbers Report

By The Numbers Chart

Top Performers


The QualityStocks Sponsored News


The QualityStocks DailyNetwork Sponsors

CannabisNewsWireCanadianCannabisNewsWireCNW420CannabisNewsWatchCBDWireCryptoCurrencyWireGot Stocks?Got Stock Tips?Green On The StreetHempWireNewsInvestorOutreachCenterMissionIRMissionIR MediaMissionPR MissionSMRNetworkNewsWireNetworkNewsWatchNetworkWireQualityStocks MediaQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsSmallCapSocietyTiny GemsTip.usTraderPower

ActionStockPicksAgressive StocksBetting On Wall StreetGreen Car StocksGreen Energy StocksHomeRunStocksInvestorBrandWireQStocksStock BeatsStockTipsStocks To Buy NowTerrificStocks

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.

The QualityStocks Numbers Report

By The Numbers Chart

Top Performers


QualityStocksTwits

QualityStocksTwits is your stock tracking service portal to Twitter's universe of stock picks, commentary and research.

Visit Portal


The QualityStocks Sponsored News


The QualityStocks DailyNetwork Sponsors

CannabisNewsWireCanadianCannabisNewsWireCNW420CannabisNewsWatchCBDWireCryptoCurrencyWireGot Stocks?Got Stock Tips?Green On The StreetHempWireNewsInvestorOutreachCenterMissionIRMissionIR MediaMissionPR MissionSMRNetworkNewsWireNetworkNewsWatchNetworkWireQualityStocks MediaQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsSmallCapSocietyTiny GemsTip.usTraderPower

ActionStockPicksAgressive StocksBetting On Wall StreetGreen Car StocksGreen Energy StocksHomeRunStocksInvestorBrandWireQStocksStock BeatsStockTipsStocks To Buy NowTerrificStocks

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.

The QualityStocks Numbers Report

By The Numbers Chart

Top Performers


QualityStocksTwits

QualityStocksTwits is your stock tracking service portal to Twitter's universe of stock picks, commentary and research.

Visit Portal


The QualityStocks Sponsored News


The QualityStocks DailyNetwork Sponsors

CannabisNewsWireCanadianCannabisNewsWireCNW420CannabisNewsWatchCBDWireCryptoCurrencyWireGot Stocks?Got Stock Tips?Green On The StreetHempWireNewsInvestorOutreachCenterMissionIRMissionIR MediaMissionPR MissionSMRNetworkNewsWireNetworkNewsWatchNetworkWireQualityStocks MediaQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsSmallCapSocietyTiny GemsTip.usTraderPower

ActionStockPicksAgressive StocksBetting On Wall StreetGreen Car StocksGreen Energy StocksHomeRunStocksInvestorBrandWireQStocksStock BeatsStockTipsStocks To Buy NowTerrificStocks

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.